Podcasts about Cart

Broadcast from KSQD, Santa Cruz on 1-01-2025: An emailer asks about omega-3 supplementation for memory at age 72. Dr. Dawn advises checking that fish oil capsules contain adequate DHA—at least 1,000 mg—since many omega-3 products have low DHA levels. She notes Medicare covers the same testing at standard labs as proprietary labs like OmegaQuant that charge patients directly. Beyond omega-3s, she emphasizes glucose control (hemoglobin A1c below 5.6) since the enzyme that breaks down insulin also clears beta-amyloid, and weight training to raise brain-derived neurotrophic factor (BDNF), which promotes new synapse formation essential for memory. Dr. Dawn reviews Popular Science's top 2025 health innovation: eye drops from Lens Therapeutics containing aceclidine that correct age-related farsightedness for 10 hours. The drops shrink the pupil to increase depth of field, improving near vision by three or more lines on eye charts within 30 minutes without affecting distance vision. Side effects include eye irritation, dimmed night vision, and headache. She describes Duke University's breakthrough allowing heart transplants from circulatory death donors using an on-table reanimation technique. This could expand the pediatric donor pool by 20%—critical since up to 20% of children die waiting for transplants. Dr. Dawn celebrates CAR-T immunotherapy for multiple myeloma, which saved her husband's life. Of 97 heavily pretreated patients, 38% achieved complete remission still present at five years, with over 50% total survival. The therapy removes T-cells, uses CRISPR to add receptors targeting cancer cell antigens, then reinfuses the modified cells. She highlights a UC Davis study showing remote blood pressure monitoring with home technology, education, and coaching dropped patients' average blood pressure from 150/80 to 125/74 in months—low-tech with high impact. Dr. Dawn explains the Nano Knife for prostate cancer, which uses localized electrical pulses delivered through thin wires to destroy tumors while sparing surrounding nerves. This minimally invasive approach could reduce erectile dysfunction and incontinence common with traditional surgery. She describes Gilead's Sunlenca, a twice-yearly injection for HIV prevention that's 99% effective. At $14,000 per injection in the US, proceeds help fund access in resource-limited countries where it can be distributed like a vaccination. Dr. Dawn discusses Journavx (suzetrigine), a new non-opioid pain medication working on sodium channels to block pain signals before reaching the brain. At $30 for 50 pills on GoodRx, it offers an alternative for surgical pain in patients with addiction history or genetic vulnerability to opioid dependence. She details the landmark case of Baby KJ, the first person to receive personalized CRISPR gene therapy. Born with a CPS1 enzyme deficiency causing toxic ammonia buildup, KJ was too small for liver transplant. Scientists identified his specific mutation and used CRISPR base editing delivered via lipid nanoparticles to correct a single DNA letter—changing an A to G—in his liver cells which restored enough function to be discharged home. Dr. Dawn reports surprising findings that COVID mRNA vaccines amplify cancer immunotherapy. Lung cancer patients who received COVID vaccination within 100 days of checkpoint inhibitor treatment had 56% three-year survival versus 31% for unvaccinated patients. The mechanism is unknown but may involve mRNA generally alerting the immune system. She revisits research showing Zostavax shingles vaccination reduced dementia risk by 20% over seven years. A natural experiment in Wales—where an age cutoff created comparable vaccinated and unvaccinated groups—provided strong evidence that preventing herpes zoster inflammation protects brain health. Dr. Dawn concludes with Huntington's disease breakthrough: microRNA therapy delivered by virus directly into the brain slowed disease progression by 75% over three years. The microRNA binds to Huntington protein mRNA, preventing ribosome translation and toxic protein production. Some patients returned to work; others expected to need wheelchairs are still walking.

​ This week we discuss stem cells.  Having great therapeutic and biotechnological potential, stem cells are extending the frontier in medicine. Not only replace dysfunctional or damaged cells, the so-called regenerative medicine, stem cells may also offer us new perspectives regarding the nature of aging and cancer. This review will cover some basics of stem cells, their current development, and possible applications in medicine. Meanwhile, important remaining challenges of stem cell research are discussed as well. ​Stem cells are unique, unspecialized cells that can divide to create more stem cells (self-renewal) and can transform (differentiate) into various specialized cells, acting as the body's repair system to generate new cells for growth, repair, and maintenance, with different types existing in embryos (pluripotent) and adults (multipotent) and being studied for treating diseases like paralysis, diabetes, and heart disease.   Types of Stem Cells Embryonic Stem Cells: Pluripotent (can become almost any cell type) and come from early embryos.  Adult Stem Cells (Tissue-Specific): Multipotent (limited to certain cell types within their tissue) and found in adult organs like bone marrow, skin, and the brain.  Induced Pluripotent Stem Cells (iPSCs): Adult cells reprogrammed in the lab to act like embryonic stem cells, offering a path to personalized medicine.  ​Sources of Stem Cells Embryos (for research), Umbilical cord blood, Bone marrow, Other adult tissues (like fat or skin). ​Medical Significance (Stem Cell Therapy) Regenerative Medicine: Uses stem cells to repair or replace damaged tissues and organs.  Treatments: Already used to treat blood cancers (like leukemia) through bone marrow transplants.  Research Focus: Investigated for treating conditions such as spinal cord injuries, Parkinson's, Alzheimer's, heart disease, and diabetes.  ​There is some stem cell controversy, primarily centering on the ethics of using human embryos, particularly embryonic stem cells, which hold vast potential for medicine but require destroying the embryo, raising moral debates about the embryo's status as human life, with opponents seeing it as the destruction of life and proponents viewing it as a moral imperative to cure disease, though adult stem cell research and induced pluripotent stem cells (iPSCs) offer less controversial avenues.  We don't discuss this aspect of the therapeutic use but if you are interested you can find out more with a simple internet search. ​Stem cell therapy in the US is not banned but restricted. Only FDA-approved products (such as cord blood transplants and CAR-T cell therapies for blood conditions) are fully legal. Other uses are allowed only in limited cases under the 361 HCT/P pathway.

Dr. Lisa Hicks and Dr. Joseph Mikhael discuss the updated guideline from ASCO and Ontario Health (Cancer Care Ontario) on the treatment of multiple myeloma. They cover recommendations for therapeutic options across smoldering multiple myeloma, transplant eligible multiple myeloma, transplant ineligible multiple myeloma, and relapsed or refractory multiple myeloma. They highlight the importance of shared decision making and patient-centric care. They comment on the explosion of new treatment options in this space and the impetus for this guideline becoming a living guideline, which will be updated on an ongoing, regular basis. Read the full guideline, "Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline" at www.asco.org/hematologic-malignancies-guidelines. TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/hematologic-malignancies-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02587   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Lisa Hicks from St. Michael's Hospital and University of Toronto, and Dr. Joseph Mikhael from the Translational Genomics Research Institute, an affiliate of City of Hope Cancer Center, co-chairs on "Treatment of Multiple Myeloma: American Society of Clinical Oncology-Ontario Health (Cancer Care Ontario) Living Guideline." Thank you for being here today, Dr. Hicks and Dr. Mikhael. Dr. Lisa Hicks: Thanks so much. Dr. Joseph Mikhael: It is a pleasure to be with you, Brittany. Thank you. Brittany Harvey: Before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Hicks and Dr. Mikhael who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into what we are here today to talk about, Dr. Mikhael, I would like to start by recognizing that this guideline updates the 2019 ASCO-CCO Guideline on the Treatment of Multiple Myeloma. So what prompted this update and what is the scope of this updated guideline? Dr. Joseph Mikhael: It is amazing when we think back in myeloma years, 2019 actually seems a very, very long time ago because really so much has changed in myeloma over these last six to seven years. Indeed, there have been over 150 randomized controlled trials that we didn't have at the prior guideline that we reviewed for this. Myeloma is a disease that has really changed so dramatically over these last several years. Multiple new agents have been introduced. We now have CAR-T cell therapy, bispecific antibodies, and multiple other agents that were not available at the time. Furthermore, with this growing complexity, it is becoming more important than ever to be able to provide practical advice and guidelines to the oncology community. For most oncologists, they have less than 5% of their time dedicated to multiple myeloma. It is important to bring a clarity to them that allows them to care for their patients. And the scope of these guidelines, furthermore, really cover the whole spectrum of myeloma. They go further than our prior guideline where now we have included smoldering multiple myeloma along with frontline therapy and relapsed multiple myeloma. So, we have really tried to provide the full spectrum to our colleagues in oncology to ensure that they have the tools they need to provide the best care possible for their patients. Dr. Lisa Hicks: That is a really terrific summary. And maybe one thing I will just add is it is really unique to have this much literature. I can't think of another guideline that I have ever been involved with that has seen a field move so quickly and develop so many advancements in a period of just over four or five years. Brittany Harvey: Certainly, there is a large volume of evidence that you all had to review for this guideline update. I think to your point probably one of the greater volumes of literature for a guideline update that you both mentioned. Based on that, I would like to review the key recommendations that are updated in this guideline. So Dr. Hicks, that new patient population that Dr. Mikhael mentioned earlier, what are the key recommendations for patients with smoldering multiple myeloma? Dr. Lisa Hicks: So this is the first time that an ASCO guideline is addressing this branch of multiple myeloma care. It is an area where I think some guidance is needed, and smoldering myeloma is not an active cancer. And so one thing that I really want to highlight is that the panel felt very strongly that to recommend any therapy in this space we needed a higher level of evidentiary certainty, of evidentiary confidence, to make recommendations for active therapy. The panel really made two very important recommendations. First of all, the panel did not recommend treatment for low or intermediate risk smoldering myeloma. That is important. And then the area where I think for the first time we have recommended consideration of treatment is patients with high risk smoldering myeloma. And for patients with high risk smoldering myeloma, the panel recommended that it was appropriate to consider either treatment with daratumumab or careful observation. Dr. Joseph Mikhael: And I think that move forward as you have mentioned, Dr. Hicks, is particularly important because it is an area to some degree still of equipoise and many trials are going on in the area. But we do now have a strong phase III trial that supports the use of daratumumab monotherapy for three years when compared to close observation. But of course, that is not for everyone. And one of the key themes of all of our recommendations are going to be now that more and more choices are available, that we have discussions with our patients to ensure that we match the right treatment with the preference of the patient. And I think that is particularly important here in smoldering myeloma. Dr. Lisa Hicks: Multiple myeloma care and the multiple myeloma evidence is really so nuanced, and one of the nuances that readers will appreciate if they read the guideline is that how smoldering myeloma is risk stratified has been different across different trials. And that really adds to the complexity of this recommendation and is one of the reasons that the panel felt that it was appropriate to recommend either observation or treatment. Brittany Harvey: It is great to have these new recommendations for this unique patient population. And as you both mentioned, that individualized patient care is really important across this entire guideline. So then following those recommendations, Dr. Mikhael, what is recommended for initial therapy, autologous stem cell transplantation, post transplant therapy, and measurement of response for patients with transplant eligible multiple myeloma? Dr. Joseph Mikhael: Well, that is an area that has really considerably also grown since the last guideline. Obviously one would have to consult the guidelines to get every last detail, but in essence, we want to assess whether or not patients are transplant eligible or ineligible. And that assessment is not based on age or renal function alone, but indeed on a careful assessment of that patient. When that assessment is made and deemed that a patient is transplant eligible, our recommendation is that a patient typically would receive a quadruplet. That is to say, a monoclonal antibody directed against CD38, a proteasome inhibitor, an immunomodulatory drug, and dexamethasone to be given for approximately four to six cycles followed by the stem cell transplant, followed by potentially another two cycles of consolidation, and then maintenance therapy. A couple of important caveats. One, we do have two different CD38 antibodies that can be used, either daratumumab or isatuximab. Although typically bortezomib is the preferred proteasome inhibitor, consideration can be given to carfilzomib by virtue of the potential toxicity from bortezomib. And then lastly in the maintenance setting, we are typically recommending at least lenalidomide alone, but consideration can be given to dual maintenance therapy as the data is emerging to either add to that daratumumab or carfilzomib. All the while using the IMWG criteria for response. The goal of course is to achieve the deepest response possible and to maintain that response until such time as patients would relapse. Finally, the length of maintenance therapy continues to be an area of equipoise and study in multiple myeloma. And so at minimum, patients would receive two to three years of maintenance therapy, and based on risk status and depth of response it can be considered that patients would potentially come off maintenance therapy, of course always with the caveat that toxicity would influence length of therapy as well. Brittany Harvey: Yes, as you mentioned, evaluating which patients are eligible is extremely important for considering what is recommended in the guideline for both transplant eligible and transplant ineligible patients. So then Dr. Hicks, following those recommendations for transplant eligible multiple myeloma, what are the recommended treatments, goals of therapy, and measurement of response for patients with transplant ineligible multiple myeloma? Dr. Lisa Hicks: You know, I really can't emphasize enough how important an individualized patient assessment is. When we are thinking about the range of patients that are included in this category of transplant ineligible patients, it is a huge range. You may have fairly fit patients in their late 70s all the way to patients in their 90s. And we really want to see that treatments are tailored both to the fitness of the patient, their individual circumstances, and their preferences. And it is a wonderful thing to have lots of options for patients in this circumstance. What the guidelines have recommended for most patients who are transplant ineligible but fit enough for a stronger therapy is quadruplet therapy. So actually therapy that is very similar to what is being recommended in the transplant eligible population but for a longer period of time. And then for those patients who for whatever reason, be it their fitness or their preference, are not appropriate for that quadruplet therapy, the recommendation is for triplet therapy with a combination of lenalidomide, bortezomib, dexamethasone, or very often, more often in most cases, an antibody based approach with an anti-CD38 plus lenalidomide plus dexamethasone. Dr. Joseph Mikhael: The only thing I would add to that, I think we have to also, as we do mention in our recommendations, be particularly cautious with the dosing of these medications. Because even though we think of them as a single agent or a particular class, there can be quite a variation within the dosing regimen that can affect a patient's side effects and their quality of life. And so being very careful with dose modifications, and particularly in the transplant ineligible patient, is an important part of the recommendation as well. Dr. Lisa Hicks: Yeah, this is a podcast so no one can see me nodding vigorously that dose modification is so important particularly with those older and frailer patients, and with particular attention to trying to reduce dexamethasone doses and favoring weekly administration of bortezomib when that drug is used. Brittany Harvey: Absolutely. Considering the risks and benefits and patient preferences is really key to selecting therapy for these patients. So then Dr. Mikhael, for the final overarching patient population addressed in this guideline, for patients with relapsed or refractory multiple myeloma, what treatment options are recommended? Dr. Joseph Mikhael: This of course is, if you will, the biggest part of the guideline because there has been so much done in the relapse setting. And I think we start the guideline by saying a decision has to be made as to when to institute therapy. That there may be some patients with slow biochemical relapse that may be monitored for a period of time. But when the decision is made to initiate treatment, instead of a simple algorithm, the guideline emphasizes the fact that there are multiple choices that can be given to a patient that are going to match what comorbidities the patient has, what they have been treated with before, and of course what their preferences are. I think we highlight two particular areas. That now that CAR-T cell therapy is available as early as first relapse, it should be a consideration by virtue of the fact that it has resulted in such deep and durable responses. But that triplets should also be considered in that earlier relapse setting because we do have multiple classes of agents that can be used. We know that in later relapse options exist including bispecific antibodies for which we have four different choices. And that in general, patients will ultimately receive either a triplet or CAR-T cell therapy in earlier relapse, but there are some patients who may be eligible only for a doublet by virtue of their comorbidities and of their prior therapies. Lastly, it really does emphasize the point as we have mentioned a few times in this podcast, and I am so glad it keeps coming up, is that as I often say we don't treat myeloma, we treat people. And engaging the patient in that conversation to ensure that the right treatment gets matched to the right patients is particularly important because with all the new classes that we have with antibody drug conjugates, with XPO1 inhibitors, the traditional three classes of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, along with as we have already mentioned CAR-T and bispecific antibodies, it really is an incredible laundry list of choice. And making that choice specific to the patient becomes absolutely critical. I should also lastly note that there are patients who may defer their initial transplant. There may be patients who may be eligible for a second transplant. So autologous stem cell transplant, although primarily used in the frontline setting, may still be a consideration for a smaller subset of patients in the relapse setting. Dr. Lisa Hicks: I think maybe one thing that I would add is an overarching principle which is actually similar to a principle in the first guideline, and that is that in the relapsed or refractory setting, there are many different treatment options. And in fact, the number of treatment options feels like it is evolving every day. But an overarching principle for clinicians to consider is to try and choose combinations of drugs that the patient has either not been exposed to in the past or certainly that they are not refractory to. We really want to be pulling new options out of the toolbox as much as we can. Dr. Joseph Mikhael: Very often we do see where someone may be on a triplet and they are progressing on it and someone just changes out one drug. We have suggested not to take that approach but to take the approach of completely introducing a new therapy when someone is progressing on their current therapy. I think that point is particularly important and the consensus panel was very clear. Brittany Harvey: Understood. That is very helpful when thinking about what options to offer to patients in the relapsed and refractory setting. And as you mentioned earlier, the figures in this guideline provide an outline of options and then the tables really go into some of the details and outcomes of the trials, and those are very helpful for clinicians to refer to. So then Dr. Hicks, we have talked a little bit about some of the nuances of the guideline, but what should clinicians know as they implement these new and updated recommendations? Dr. Lisa Hicks: I think they should feel comfortable that these are trustworthy guidelines. So these are evidence-based guidelines that have been rigorously developed after a very thorough evidence review and put together by a panel of experts who were extremely thoughtful in their review of the evidence. And so all of this contributes to the trustworthiness of the guidance. And then I would also encourage people to take a deep look at the guidelines because of the importance of nuance that is addressed in them, and then to also explore some of the tools that ASCO is developing that helps with implementation including the flow charts that are contained within the guidelines and some additional tools that are available online. Brittany Harvey: Absolutely. The tools and resources for this guideline are available online with the publication and we will provide links to that in the show notes of the episode. So then following that, Dr. Mikhael, how does this guideline update affect patients with multiple myeloma? Dr. Joseph Mikhael: As we sort of intimated earlier, I like to say I don't treat myeloma, I treat people. I think we should always be patient-centric and patient-focused. And I think in the discussion we always were. We always wanted to ensure that multiple factors go into a decision-making process. We are not just looking at the biology of the disease, we are looking at patient factors. Those patient factors include their frailty as we commented in a frailty assessment, their preferences, their comorbidities. And I think, in a day where we have so many choices, we emphasize in the guideline the importance of that conversation with the patient. That, if you will, shared decision-making model where options are laid out and based on the patient factors and the treatment factors they can then be meshed together in the best way so that patients can make the right choice. And of course in conjunction with the guidelines, we have patient friendly summaries of them. And we involved, of course, patients in the development of these guidelines. And I think that is one of the greatest strengths of the ASCO guidelines is that there is a patient with us at the table who is giving their perspective on the guideline as we go forward. So I am very thankful that we have created a product that is, if you will, not only for the providers, the practitioners that are prescribing these agents and that are directly giving the care, but indeed for the very patients who of course have the most at stake here. Dr. Lisa Hicks: Yeah Joe, I am so glad you called out the participation of patient partners in the guideline. It is such an important part and they were really- the patient partner was such an important part of this panel in helping us understand the patient perspective as we developed this guidance. Brittany Harvey: Definitely. It is a hugely important role for the panel and for all of the panel including the patient partners and the experts in the disease to review the evidence and come up with comprehensive recommendations. And yes, as you mentioned, the individualized treatment and the shared decision-making is really paramount to this guideline. Finally, Dr. Hicks, you alluded to earlier the vast number of treatment options that is really exploding in multiple myeloma. And so this guideline is becoming a living guideline continuously updated by ASCO. So what are the outstanding questions regarding this topic and what evidence is the panel looking forward to for future updates? Dr. Lisa Hicks: I am really excited about this. This is one of the first guidelines that will be a living guideline for ASCO and it is such a good fit. You have heard Joe and I say a few times how quickly this field is moving, how complex the field is. I think everyone on the panel knew that no matter how quickly we did it and how deeply we reviewed the evidence, it was inevitable that more evidence would be generated as we were putting out the guideline. In a field like that, it is really important that we find a way to provide evidence-based guidelines quickly to the community. You know, waiting another five years, letting another 150 trials accrue before we do another guideline is not what the community needs. And so ASCO has really risen to this challenge and is committed to living guidelines. And so a living guideline is a guideline that commits to reviewing the evolving evidence on an ongoing basis, watching for practice changing trials, and having a standing panel that will review evidence and update recommendations on a regularly scheduled basis. So that is what a living guideline is, and that is what this guideline is becoming. That is just the first thing in terms of what a living guideline is. And then what are we watching? Well, honestly what aren't we watching? There is so much happening in multiple myeloma. We knew as we put the guideline out that there were trials in process, some trials that had been released at conferences but not yet published. We will be waiting for those and if they are practice changing they will be addressed in upcoming updates. There is new evidence just recently presented around combined anti-CD38 and bispecific antibodies. I don't know yet whether that will be addressed but I wouldn't be surprised if it was. There are so many things coming down the pipeline and it is just wonderful that there is going to be a way to try and address them in a robust fashion. Dr. Joseph Mikhael: Yeah I agree with you, Lisa. I can't think of another disease that would be more relevant for a living guideline. I mean we had difficulty because new data kept coming in as we were making recommendations. And so at some point we had to draw a line and say this is where we will stop and produce this guideline and have it ongoing. And I really look forward to seeing the updates because we know as you mentioned that there are so many things that are on the verge of approval and on the verge of changing the way we manage this terrible disease. And before I close, I would love to remind all of our listeners that as we commented from the start, patient engagement is critical at ASCO and in our guidelines process. Unfortunately we lost a very dear patient during the guidelines process, and that is Jack Aiello. Jack Aiello had been a patient and a patient advocate for many, many years in the myeloma community. And indeed we have actually dedicated these guidelines to his honor. And so I thought it would be valuable for us to mention that today. And we miss you Jack, but we are very grateful that we have been able to dedicate this excellent body of work to your memory. Brittany Harvey: Absolutely. This guideline and your dedication to him is an honor to his memory and we really recognize him in thinking about this guideline. We will look forward to those future trial results that you mentioned, Dr. Hicks, to update this guideline and continue to provide options for patients with multiple myeloma and improve upon those options and shared decision-making with patients. So I want to thank you both for all of your work to develop this guideline and for your time today, Dr. Hicks and Dr. Mikhael. Dr. Lisa Hicks: You are so welcome. Thanks for featuring this guideline. Dr. Joseph Mikhael: Thank you so much, Brittany. It has been a privilege. Brittany Harvey: Finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/hematologic-malignancies-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App, which is available in the  Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Aurora returns from a dinner party with a new, dubious alliance with Draken. Frustrated, she attempts to seek council with the mysterious woman who calls herself her "friend" and discovers something about herself and her deepest desire. As Aurora contemplates her growing thirst for power, the lines between friend and foe blur even further, and the seeds of doubt and ambition begin to take root in her mind.A Tale of Remembrance serves as an integral mini-series within the Sword Art Online: AOD campaign, unveiling the enigmatic backstory of a pivotal character. It stands as a compelling prelude to the events of season 4.Contact Us:Email: info@missingrollplayerfound.comFollow Us:Website: https://missingrollplayerfound.com/Linktree: https://linktr.ee/rollfoundSupport Us: Please consider contributing to the production of the podcast.Patreon: https://patreon.com/missingrollplayerfoundDice Envy (affiliate): https://diceenvy.com/?rfsn=2188188.53cb38Battlebards (affiliate): https://battlebards.com/#/register/mrpfpodMusic Attribution: (To be updated)Dark Fantasy Studio (A Band in the Inn, Dark Echoes)Link: http://darkfantasystudio.com/Kevin Macleod (The Dread)Link: https://incompetech.com/Michael Ghelfi (Burning Fields with Distant Screams)Link: https://www.youtube.com/user/MichaelGhelfiMonument Studios (Anticipation Ambience, Astral Observatory, Horseback, Horse & Cart, Countryside, Evening in the City, Friendly Woodwinds, Quiet Tavern, Raided Village, Vigor)Link: https://www.monumentstudios.net/Music D20 (Helgisidur Just Percussion)Other Music and Sounds by Syrinscape Link: https://syrinscape.com/?att_missing_roll_player_found Because Epic Games Need Epic Sounds Support this podcast at — https://redcircle.com/missing-roll-player-found2852/donations

 Join hosts Raj, Ashwin, and Eddie in this episode of Blood Cancer Talks as they welcome Dr. Luciano Costa, the first author of the NEJM manuscript on the MajesTEC-3 RCT, which was presented at ASH 2025. This episode dives deep into the trial's topline findings, capturing the nuances of the patient population, efficacy and safety data, and the future implications for treatment. The episode also examines the comparative efficacy of bispecific T-cell engagers versus CAR-T therapies, along with spirited discussion on the potential for fixed-duration treatment in myeloma care. Episode Highlights Main Topics Covered MajesTEC-3 Trial: Teclistamab-Daratumumab vs. Standard of Care Trial design and patient populationPrimary endpoint: Progression-free survival (PFS)MRD negativity rates and depth of responseOverall survival and safety profileClinical implications for treatment selectionTreatment Selection in Early Relapse Comparing MajesTEC-3 and CARTITUDE-4 patient populationsFramework for choosing between bispecific antibodies vs. CAR T-cell therapyManaging anti-CD38 exposed patientsLink to the NEJM paper: https://www.nejm.org/doi/abs/10.1056/NEJMoa2514663  

Équipe suspendue, encadrement démis et mise à l'écart de Pierre-Emerick Aubameyang et Bruno Ecuele Manga : l'élimination au premier tour de la Coupe d'Afrique des Nations passe mal au Gabon, où le ministre des Sports a annoncé des sanctions. Face à la Côte d'Ivoire, la sélection gabonaise s'est inclinée (3-2) mercredi, pour la troisième fois en trois matches. Aubameyang se défend dans un tweet : "Je pense que les problèmes de l'équipe sont bien plus profonds que la petite personne que je suis".

In this week's episode we've pulled a vault recording from 2025! Blood editor Dr. Laurie Sehn interviews authors Drs. David-Alexandre Trégouët and Johannes Schetelig on their research published in volume 146 issue 19 of Blood journal. Dr. Trégouët's study conducted a genome-wide association study supplemented by transcriptome and Mendelian randomization analyses to identify 28 loci and proteins associated with VTE recurrence risk. This work provides genomic evidence that inherited variants contribute to the risk of VTE recurrence, raising the possibility of a more personalized approach to the prevention of recurrent VTE. The study conducted by Dr. Schetelig and colleagues report the results of a long term trial on patients with poor-response AML, comparing outcomes between patients who received salvage chemotherapy versus immediate transplantation. With no difference in survival rates at 5 years, outcomes seem to be determined mainly by genetic risk factors, age, and comorbidities, therefore challenging the routine use of intensive remission induction before allogeneic transplant in patients with an available donor and underscore the need for novel therapeutic strategies for poor-risk AML.Featured Articles:Molecular Determinants of Thrombosis Recurrence Risk Across Venous Thromboembolism Subtypes Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial 

REDIFF - Lola se sent mise à l'écart et en manque de chaleur dans sa relation avec son plus jeune fils, récemment marié. Elle éprouve des difficultés à s'adapter à la nouvelle dynamique familiale, notamment en raison de différences sociales et culturelles avec la belle-famille. Elle cherche à comprendre comment maintenir une relation chaleureuse avec son fils tout en gérant ses propres sentiments de solitude et d'insécurité.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Week 17 brought Evan another fresh batch of season-ending injuries and Frank the division title! The boys recap an embarrassing Saturday performance in Lambeau by the beleaguered Packers that handed the Bears the NFC North crown before their epic showdown in the Bay on SNF. Plus, a look forward at potential playoff scenarios for both teams and a not-so-civil discussion on the future of Matt LaFleur.

Breakthrough science has never been stronger — yet patients still miss life-saving therapies.Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery.The problem isn't discovery. It's how science, capital, and systems are aligned — or not.Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem.As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge scientific depth with incentives, execution, and real-world delivery. Capital follows speed and scale — not intention — and healthcare systems built decades ago are failing to keep up.In this episode, Alasdair Milton, Principal at KPMG, explains where innovation actually breaks — and what must change for cures to reach patients at scale. From diagnostics and data silos to capital allocation and prevention models, this conversation reframes the next decade of precision medicine.

After the 2025 American Society of Hematology (ASH) Annual Meeting had passed, the  data were out, and the hematologist/oncologists of the world had time to digest the practice changes that awaited them upon their returns home. Rahul Banerjee, MD, FACP, and Brooke Adams, PharmD, BCOP, took part in an X Spaces discussion hosted by CancerNetwork® in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT) to highlight these potential changes. Adams and Banerjee discussed abstracts from the meeting, including the phase 3 MajesTEC-3 trial (NCT05083169), which evaluated teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma who progressed on at least 1 prior line of therapy.1 A significant progression-free survival benefit was observed with the experimental combination compared with standard of care in this population. They also discussed data from cohort A of the phase 2 IFM2021-01 trial (NCT05572229), which evaluated subcutaneous teclistamab in combination with subcutaneous daratumumab in patients with newly diagnosed multiple myeloma. Results demonstrated that the combination was effective and safe in the frontline treatment of patients who were ineligible for transplant.2 The discussion also covered the broader treatment landscape, as the experts compared the use of bispecific antibodies with BCMA-directed CAR T-cell therapies. Frontline bispecific strategies for transplant-ineligible populations were also topics of conversation, as well as post-transplant consolidation with bispecifics. Ultimately, they stated that multiple myeloma care is undergoing a paradigm shift toward deeper minimal residual disease negativity, possible treatment de‑escalation, and even serious use of the word “cure” for the disease. Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center, and Adams is a clinical pharmacist in the Department of Stem Cell Transplant and Cellular Therapy and coordinator of the PGY-2 Oncology Residency at Orlando Health. Both are also members of the ASTCT content committee. References Mateos M-V, Bahlis N, Perrot A, et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3. Blood. 2025;146(suppl 2):LBA-6. doi:10.1182/blood-2025-LBA-6 Manier S, Lambert J, Marco M, et al. A phase 2 study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: the IFM2021-01 teclille trial, cohort A. Blood. 2025;146(suppl 1):367. doi:10.1182/blood-2025-367

What if the knowledge we depend on today... disappeared tomorrow? Have you ever wondered how much of humanity's greatest achievements have already been lost to time?Do you suspect that ancient civilizations knew things we are only now beginning to rediscover?Do you worry that our own digital civilization might be far more fragile than we think?If so... keep reading.For thousands of years, human knowledge has risen, vanished, and—sometimes—been found again.From medical breakthroughs in ancient Egypt to astonishing feats of engineering by cultures we barely remember, history shows a repeating pattern: discovery, prosperity... and catastrophic loss.Now, with our reliance on digital systems and complex global networks, we may be closer than ever to our own "forgotten age."https://jrbialik.com/Drawing on over 40 years of professional experience in engineering, technology, and history—including work with the U.S. Air Force, the Department of Homeland Security, and contributions to critical technology programs—Jack R. Bialik takes you on a journey across centuries of lost civilizations, vanishing wisdom, and the fragile threads holding our modern knowledge together.Here's a glimpse of what you'll discover inside Lost in Time: How cataract surgery was successfully performed in 2400 BC Egypt—and why we nearly lost that knowledge forever.The shocking truth about technologies invented thousands of years earlier than historians once believed.Forgotten disaster events that erased entire libraries of human understanding in a single day.The hidden risks of a fully digital society—and what history teaches us about protecting what matters.Lessons from the past that can guide business leaders, educators, and decision-makers today.How to recognize the warning signs of a coming knowledge collapse....and much more.You might think a book like this requires deep academic expertise to follow—it doesn't. Bialik's clear, compelling style makes these stories accessible for curious readers, history lovers, business travelers, and lifelong learners alike.If you're ready to explore the mysteries of humanity's greatest achievements—and learn how we can prevent them from disappearing again—scroll up and click "Add to Cart" now!Jack R. Bialik's 40-year career spans from Electrical Engineering and Project Management to biblical studies, with notable contributions to organizations like the U.S. Air Force and the Department of Homeland Security. His industry-impacting paper, presented at the Motorola System Symposium 2000, stands out among his many achievements. His unique expertise led him to be invited to be a reviewer for the White House's Broadband Technology Opportunities Program, marking another career highlight. Today, as the Chief Technology Officer of a niche Crypto-Mining company, he continues influencing the technology landscape. However, Jack's interests extend beyond his profession, with a certificate from the Awakening School of Theology and his interest in ancient history. His commitment to societal welfare is seen through his involvement with at-risk teens and clean water initiatives in Haiti. Jack is a consummate professional and committed humanitarian, exemplifying the power of lifelong learning and altruism.Become a supporter of this podcast: https://www.spreaker.com/podcast/earth-ancients--2790919/support.

Send us a textWe weren't planning on dropping another episode before the new year, but when the timing feels right, you listen.This is a special holiday re-share of my conversation with Vanessa Torres from Freedom a la Cart, an organization doing some of the most important, powerful work in our community.In this episode, Vanessa shares her personal story of surviving human trafficking and what real healing actually looks like when someone is met with safety, employment, community, and time. We talk about trauma bonds, recovery, motherhood, and the long road back to trust. Both in others and in yourself. It's honest, heavy at times, and deeply human.We're bringing this conversation back right now because Freedom a la Cart, like many nonprofits, was recently denied grant funding they were counting on. In response, their team launched an end-of-year giving campaign to help bridge the gap and continue supporting survivors during a season when the need is especially real.If this episode moves you, you'll find a link to their Freedom Matters campaign below. Whether you give, share, or simply listen with intention. Every bit of support matters.✨ Learn more or support their campaign here: https://freedomalacart.org/freedom-matters/Thank you for being here and for being part of a community that shows up when it counts.

This Editor's Special Episode of The HemOnc Pulse features Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discussing treatment strategies for relapsed/refractory multiple myeloma and where selinexor-based regimens fit in today's evolving landscape. Drawing from real-world cases, Dr. Richardson explores care for patients before CAR T, after CAR T relapse, and in between—highlighting how selinexor can be used flexibly across multiple lines, including as a bridge to future immunotherapies. The conversation emphasizes individualized, dynamic treatment planning to balance disease control, tolerability, and long-term goals in an increasingly complex era of myeloma care.

In this episode our host Dr Raquel Faria, together with Professors David Isenberg and Richard Furie, explore the first major update to the Lupus Treatment Guidelines in 25 years, highlighting aggressive steroid sparing, universal hydroxychloroquine use, and the revolutionary potential of CAR T-cell therapy. Discover how precision medicine is shifting the standard of care from broad immunosuppression to targeted, personalized recovery. Disclaimer: During Lupus Academy podcast episodes, participants may refer to off-label use of medicines for patients with lupus. Lupus Academy does not make anyrecommendations about using a medicine outside the terms of its approved license for use.

La tertulia semanal en la que repasamos las últimas noticias de la actualidad científica. En el episodio de hoy: Cara B: -Regeneración de cartílago (00:00) -Origen policlonal del cáncer colorrectal (27:40) -Batman en el metro (52:00) -SETI@HOME. Datos y resultados (1:22:30) Este episodio es continuación de la Cara A. Contertulios: Luisa Achaerandio, Francis Villatoro, Borja Tosar, Héctor Socas. Imagen de portada realizada con Midjourney. Todos los comentarios vertidos durante la tertulia representan únicamente la opinión de quien los hace... y a veces ni eso

La tertulia semanal en la que repasamos las últimas noticias de la actualidad científica. En el episodio de hoy: Cara A: -Obituario: James Watson (10:00) -Regeneración de cartílago (48:50) Este episodio continúa en la Cara B. Contertulios: Luisa Achaerandio, Francis Villatoro, Borja Tosar, Héctor Socas. Imagen de portada realizada con Midjourney. Todos los comentarios vertidos durante la tertulia representan únicamente la opinión de quien los hace... y a veces ni eso

In this week's episode, Blood editor Dr. James Griffin interviews authors Drs. Vincent Muczynski and Mark Geyer on their latest research published in Blood. Dr. Muczynski's research asks if there could there be a better gene than the factor VIII (FVIII) gene to transfer for curative treatment of hemophilia A? Dr. Geyer then explores CAR T cells armed with interleukin-18 (IL-18) secretion that target CD371, a transmembrane glycoprotein with high expression on AML and leukemia-initiating cells. Both studies explore finding novel targets for these powerful treatment modalities. Featured Articles:Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibodyCD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia

You know what's right. But what do you do when every gatekeeper says no? In this episode, Drew Ann Long, inventor of Caroline's Cart, shares the story of refusing to let a necessary idea die. Her vision was simple—and radical: a shopping cart that makes the retail experience accessible for people with disabilities and mobility challenges. The industry pushed back. Manufacturers said no. Retailers avoided the conversation. Funding didn't show up. So she invested personally and kept advocating for a need others wouldn't acknowledge, and stayed the course anyway. Despite the special needs community being the world's largest minority group, products designed for their needs are lacking. This creates a barrier to access not only for them but for their families and caregivers. By introducing more inclusive products like Caroline's Cart, the world was opened for those with mobility challenges, autism and dementia. Success means believing in your cause and taking risks to make it happen no mater what. When the establishment tells you no, cultivate support in the community you want to serve. Innovation happens when you focus on the solution not the problem. Contact Drew Ann: https://www.drewannspeaks.com/ Donate to Caroline's Cause scholarship fund: https://www.carolinescause.com/carolines-cause/

Send us a textTheOncoPT Podcast officially turned SEVEN, y'all! And a beautiful part of being around this long means that it's time for some knowledge updates:Bone Marrow Transplant (BMT) and CAR T-cell therapy are evolving fast—are you keeping up? In this episode of TheOncoPT Podcast, Dr. Adam Matichak returns to share the latest updates on these groundbreaking treatments and what they mean for your OncoPT practice.You'll learn how CAR T-cell therapy is expanding, why mobility strategies matter more than ever, and how to use vital signs to guide your treatment decisions. Plus, we'll explore how you can advocate for rehab's role in oncology, prepare patients for complex treatments like BMT and CAR T, and find the resources you need to stay ahead in this rapidly changing field.Whether you're new to cancer rehab or a seasoned pro, this conversation will give you practical tools to treat your patients undergoing BMT and/or CAR T-cell therapy. Listen now!Follow TheOncoPT on Instagram.Follow TheOncoPT on LinkedIn.

Après les foies gras, les chapons, le Champagne et les vins mousseux, on termine le repas de Noël avec un focus sur la bûche, le dessert emblématique, de plus en plus dans sa version glacée. Côté prix, c'est le grand écart : de 3 euros à 20 euros... Ecoutez Olivier Dauvers : les secrets de la conso du 23 décembre 2025.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this episode, Shaji K. Kumar, MD, reviews key highlights from ASH 2025 in multiple myeloma (MM), focusing on emerging data for bispecific antibodies and CAR T-cell therapies across earlier and later lines of treatment. The discussion covers the following:MajesTEC-3: Results from the phase III study of teclistamab + daratumumab in R/R MM RedirecTT-1: Updated efficacy and safety of talquetamab + teclistamab in R/R MM and extramedullary diseaseCARTITUDE-4: Results following treatment with cilta-cel in patients with standard-risk cytogeneticsSTEM: Preliminary safety and efficacy data from the phase II study of cevostamab consolidation following BCMA-directed CAR T-cell therapyCAMMA1: Biomarker analyses from Arm B following cevostamab + pomalidomide and dexamethasone treatment in patients with R/R MMPresenter:Shaji K. Kumar, MDMark and Judy Mullins Professor of Hematological MalignanciesConsultant, Division of HematologyProfessor of MedicineResearch Chair, Division of HematologyMayo ClinicRochester, MinnesotaLink to full program: https://bit.ly/4995nFA Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Après les foies gras, les chapons, le Champagne et les vins mousseux, on termine le repas de Noël avec un focus sur la bûche, le dessert emblématique, de plus en plus dans sa version glacée. Côté prix, c'est le grand écart : de 3 euros à 20 euros... Cette saison dans "RTL Matin", Olivier Dauvers part à la quête des bonnes affaires et vous livre ses secrets pour éviter les arnaques et devenir un consommateur avisé ! Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

When a once-reliable podcast promo email suddenly tanks to 15% opens, you either keep pretending it's fine or you blow it up and rebuild it from scratch. You'll hear Jay Schwedelson and Amy Porterfield get honest about what changed in her newsletter, why “being more you” is now a real growth strategy, and how to experiment without freaking out when people unsubscribe.ㅤSubscribe to Amy Porterfield's newsletter, listen to The Amy Porterfield Show, and follow her on Instagram.ㅤBest Moments:(03:45) When 15% open rates forced a total newsletter reset.(05:03) Why letting your real personality show matters even more in the AI era.(07:06) Turning “YOUR cringe” feedback into a subject line that popped open rates.(08:06) The email metrics she still watches, and why beating your own baseline is the point.(13:10) Cart-close urgency is shifting, so she frontloads webinars in the first 48 hours.(17:12) The custom AI tool move that makes “just use ChatGPT” the wrong answer.ㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/

Voici deux bouteilles qui se ressemblent en apparence : même forme de bouteille, même quantité (75 cl) et même type de vin, ce qu'on appelle un vin effervescent. Mais l'une des deux bouteilles est 20 fois plus chère que l'autre... Ecoutez Olivier Dauvers : les secrets de la conso du 19 décembre 2025.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Voici deux bouteilles qui se ressemblent en apparence : même forme de bouteille, même quantité (75 cl) et même type de vin, ce qu'on appelle un vin effervescent. Mais l'une des deux bouteilles est 20 fois plus chère que l'autre... Comment l'explique-t-on ? Cette saison dans "RTL Matin", Olivier Dauvers part à la quête des bonnes affaires et vous livre ses secrets pour éviter les arnaques et devenir un consommateur avisé ! Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

“Your beliefs govern your reality.” In this episode, Nick speaks with Damon Cart, an NLP teacher and coach, about the transformative power of self-concept coaching. Damon shares his personal journey through depression, the importance of understanding one’s values, and the pitfalls of self-worth. What to listen for: Understanding your values changes how you approach achievement Self-worth is a flawed concept; it’s better to focus on values instead Taking action is crucial for gaining clarity on what truly matters Failure can lead to unexpected success “It has everything to do with your beliefs… Most people don’t believe they are the value that they’re seeking.” When you don't see your own value, you'll constantly search for it outside yourself Confidence and self-esteem are built internally, not earned through achievements Changing your beliefs about who you are opens the door to the life you actually want “If you’re adamant about being a happy and fulfilled person and you’re willing to work for it, you will get there.” You're never permanently stuck unless you stop moving toward what you want Working on yourself is an investment that pays off in how you experience life Happiness grows when you treat it like a priority, not a side quest About Damon Cart Damon is a world-leading expert in creating lasting internal transformations using the Self-Concept model™. As a master NLP practitioner and co-founder of The Self-Concept Research Group, he transformed his own life from a struggling insurance agent to a globally recognized authority in personal development. Mentored by NLP pioneer Steve Andreas, he has spent nearly eight years helping thousands achieve identity-level change. Based in Santa Cruz, California, Damon combines deep theory with practical application to make transformation effortless and permanent. https://selfconcept.com/ https://www.linkedin.com/in/damon-cart-aa79b122/ https://www.instagram.com/damoncart Resources: Interested in starting your own podcast or need help with one you already have? Send Nick an email or schedule a time to discuss your podcast today! https://themindsetandselfmasteryshow.com/podcasting-services/ Thank you for listening! Please subscribe on iTunes and give us a 5-Star review! https://podcasts.apple.com/us/podcast/the-mindset-and-self-mastery-show/id1604262089 Listen to other episodes here: https://themindsetandselfmasteryshow.com/ Watch Clips and highlights: https://www.youtube.com/channel/UCk1tCM7KTe3hrq_-UAa6GHA Guest Inquiries right here: podcasts@themindsetandselfmasteryshow.com Your Friends at “The Mindset & Self-Mastery Show” Click Here To View The Episode Transcript Nick McGowan (00:01.436)Hello and welcome to the Mindset and Self Mastery Show. I’m your host, Nick McGowan. Today on the show we have Damon Cart. Damon, how you doing today? Damon Cart (00:11.266)Good. How are you? Nick McGowan (00:12.828)I’m good, man, I’m excited. As I told you, this is the first episode of Brand New Office. So if people watch the video and I’m looking around, it’s other stuff in the office. I’m excited that you’re here, man. We were just shooting the breeze a bit before we got started and I’m excited to get into things. So why don’t you kick us off? Tell us what you do for a living and what’s one thing most people don’t know about you that’s maybe a little odd or bizarre. Damon Cart (00:23.182)you Damon Cart (00:35.694)Hmm. Well, I teach NLP and I coach it as well. I do one-on-one coaching and not just NLP. I focus on a specific model called the self concept model. And it was a model that was taught to me by my mentor, Steve Andreas. He created it. And it is a model that models our identity, how we create our sense of self and how to transform that. Most people are not living the life that they would want to be living. And that’s rooted in them not being the person they want to be. And we think that we have to go conquer mountains or defeat dragons until we’re worthy of that. And that’s just not true. It has everything to do with your beliefs and how you organize that information into those beliefs and what in fact you believe about yourself. And most people don’t believe they are the value that they’re seeking. And as a result of that, they experience lower self-esteem, lower confidence and overall just lack of fulfillment. And we can transform that and sometimes as simple as one hour session just by transforming beliefs, restructuring that information. So instead of taking years of willpower and discipline and all of those things, it’s really in how you think about it. And there’s an exact organization to that. And once you understand it, then you can change it. And something about me that is, I don’t know if I’m, I don’t know, I feel like I’m a pretty open book about things, about myself. And I don’t know of anything that I would call bizarre. would say something that probably not a lot of people know about me, unless you really know me very well, is that I’m a rather emotional person. And that can be anything. That can be anger. That can be watching a movie and, you know, feeling emotional because of it, because it’s sad or it’s a great love story or something like that. I tend to be very emotional and be The older I’ve gotten, the more comfortable I am with just being emotional and vulnerable in front of people. But I don’t really show that in my videos. In my persona online, it’s just not, I don’t think it’s really relevant. And it’s not that I’m ashamed of it. It’s just, I don’t see the value in doing that. I’m a teacher and it’s for me, it’s about getting the information out there. Nick McGowan (02:51.884)Interesting. I want to go down that path a little bit because I am emotional. If you watched any videos, you can see some of the emotions come out. There are often times I’ll blame, I’m from Philly, so I’ll just blame the Northeast. I’m like, it’s because of Philly. Like, yeah, yeah. And that’s what everybody thinks about Philly people anyway. They’re crazy or they’re loud. It’s like partially, but some of that’s also generational trauma and they don’t really know how to handle it. And Damon Cart (03:03.854)Why not? Nick McGowan (03:16.787)It’s interesting because also as we get older like you can watch a commercial and you get over 40 and you start crying and you’re like I don’t know why like what the fuck was that what a good 12 second clip of something but it’s interesting that you put that to the side when you make your videos and it sounds really conscious like you’re like I’m not gonna allow myself to be not vulnerable but emotional because you don’t want it to block the message is that about right? Damon Cart (03:43.691)You know, got a comment on one of my videos recently and that one of the live streams I did was very academic. And I was like, well, like as opposed to what, how do you, because they’re, and you’ll hear people throw this word around when it comes to NLP teachers. like, this person’s very academic. And to me, that means like more theory-based and not experiential, but NLP is very experiential. So I was just like, well, you know, how do, Nick McGowan (04:03.638)Mm-hmm. Damon Cart (04:09.358)As opposed to what I’m giving you the steps of a process that you have to go and do and experience and he was like no No, not like that. You should put your personality into your videos more and he referenced a podcast and I went and looked at the podcast and it was one of those kind like bro podcasts where It was a young man and he’s you know, kind of putting a little bit of arrogance out there No judgment on him. Like this is what plays this is what sells and So I haven’t responded to the person yet, but on my video, but basically it comes down to this I I don’t see myself as the brand of what I’m doing. The information that I’m getting out there is the star of the show, not me. And there have been times where I put my personal life on there. I’ve done vlogs and things like that. And you will see me get emotional in those. But I’ve never found it to be like why people are coming to my videos. And if my personality overshadows what I’m teaching, which is you see this in like Tony Robbins, you know, and Nick McGowan (04:46.008)Mm. Nick McGowan (05:06.915)Yeah. Damon Cart (05:06.926)Then I feel like I’m not doing my job. I feel like I’ve the message and what I’m teaching is the most important thing, not who I am. I don’t want my, if I get emotional about something, I don’t want that to hijack the video. I want the information I’m teaching to be the thing that people are coming for and that they’re getting it. Nick McGowan (05:20.653)Yeah. Nick McGowan (05:26.553)That makes total sense. And I guess to people that don’t know that, they’re just going to interpret how they’re going to interpret because we are people and we’ll interpret things how we want and make up a story and go, here’s what it is. But that’s a great way to put it. You’re stewarding it. You’re basically just letting it come through you and kind of work through you. Do you feel like some of it is also channeled in that sort of way specifically? Or are you just saying, I’ve learned this information. I want to package it in the right way so you can get the information and Damon Cart (05:38.466)Yeah. Damon Cart (05:41.826)Yes. Nick McGowan (05:56.342)Never mind how I feel about Damon Cart (05:58.735)So definitely yes to the second part, when you say channel, what do mean by channel? Nick McGowan (06:04.412)There are certain people that channel information from a higher level, from God or from the universe or whatever, and they feel that comes through them. It’s almost like how creatives or artists can say, I don’t really know where that came from, but it just came out of me and it was kind of channeled through. And I’ve seen different people and I’ve talked to different people that are like, I don’t let my vessel really, or like the being get in the way because it’s being channeled through. And it sounds like you’re taking more of the conscious approach of like the information is the information. So take the information and me being yelly or emotional about it or whatever is not going to do you a bit of good. Here’s the information. But it also sounds like that person who’s like, I want I want you to be emotional because they probably are, you know. Damon Cart (06:46.668)Yeah, and yeah, so I’ve had those moments on, because I like to do live streams. So yeah, I’ve had those moments where I felt like, yeah, I was just channeling. But majority of it is, I’ve felt this my entire life. If I was struggling to solve a problem and I solve that problem, I know that there are other people who are trying to solve that problem and they’re really frustrated. And I know what that frustration feels like. So I just want to go to them and say, here’s the key or here’s. Here’s the information you need so that you don’t need to struggle with this anymore. And I feel like that’s really my job. My channel started with one of the things I realized very quickly when I was going to like one NLP training after another, especially getting into more and more advanced NLP trainings that I was attending, not teaching, was how many people didn’t actually know basic NLP. And it was like, okay, they’re spending thousands of dollars learning all this. And it is true. Like you just don’t really get a lot of practice in NLP trainings because that would make Nick McGowan (07:34.966)Mm. Damon Cart (07:43.299)the training’s extremely long and that wouldn’t be very competitive in the market. So people aren’t really practicing and then they hand you a certificate and say, now you’re certified. And it’s like that is completely meaningless. You have to go and practice it. And so what I was doing is I was practicing every single day on myself. was practicing, I had a practice group and I would practice with them once a week and had a practice partner who I practiced with once a week. And I was practicing on people and they didn’t even realize it. I was just making the world my NLP classroom. Nick McGowan (07:44.983)Yeah. Damon Cart (08:11.054)So I was understanding NLP rapidly. And a lot of this, was not getting the help of a teacher or a mentor up until I met my mentor, Steve Andreas. And so I started my YouTube channel being that the whole point of it was I’m going to teach people what they should have learned in their NLP training. And actually to this day, when I’m going, when I’m speaking at conferences, actually when I’m shoulder to shoulder speaking with other people who are presenting at these conferences, they will come to me and say, When I was taking my NLP training, I didn’t understand what I was learning and I had to turn to your videos because your videos were the videos that actually taught me what I was supposed to know. And so I get this compliment to this day, which is a huge compliment because that’s exactly what I was set out to do in the beginning. So yeah, I’ve always, the spotlight has always been the information that I’m teaching, not me. Nick McGowan (08:46.155)Nice. Nick McGowan (08:59.383)And it sounds like with everything you’re saying, you’ve just solidified it more and more and more. Like if they were like, you know, it’s a little dry, you would probably open up a little bit in that sort of way. But the fact that you keep getting like, this is what you set out to do and this is what it’s about. That’s awesome, man. And again, I think people are gonna interpret how they want. Like I wanna hear more emotions. Damon Cart (09:17.378)Yeah, and I do share, I’m happy to share like one of the reasons why I’ve had a lot of people come to me for coaching is they would say like, you know, I heard some of what you were saying and it didn’t really speak to me, but when you talked about your depressions or you talked about your divorce and things like that. that is something that I think it helps feed what I’m trying to do here. When I, when I don’t pretend like I’m this perfect person, I think when people are trying to really build a personality brand, that’s what they’re doing. Nick McGowan (09:30.69)yeah. Damon Cart (09:45.133)And there are people who want to follow that. want to believe that there are these sort of like higher than human people that they can follow. I just, that defeats the whole point. So yeah, I want people to know that I’ve worked through problems. I’ve worked through depression. I’ve had a divorce. I’ve had to deal with, you know, trying to maintain relationships with my kids. Nick McGowan (09:45.216)Yeah. Nick McGowan (09:55.851)Yeah. Damon Cart (10:06.222)you know, in these tough times of going through a divorce and moving out of the home, you know. So I do talk about these things because I want people to understand that I’m not just like coming from a place of like, had this all figured out from the beginning. It’s like, what I’m giving you is things that, problems that I’ve solved, things that I had to figure out for myself. that’s how I know that it works. And so now I’m giving it to you. So you don’t have to stay in that frustration. Nick McGowan (10:18.443)haha Nick McGowan (10:31.273)Wait, so there aren’t perfect people on the planet? Like there’s not somebody wandering around? Like all these people on social media? Damon Cart (10:36.426)you would be amazed you would be amazed at how people really buy into that stuff and i just like yeah Nick McGowan (10:41.716)my God, well they want to, you know? Like they really want that. And I can understand like really wanting that, but it’s like self-awareness. Like once you see it, like you can’t not see things. So if you’re like, I want this, why would I want this? Well, you know, and then you kind of work through your stuff. But big thing you’re saying with this is context. Like setting the stage, giving some context to it. Like if you just talked about all these things and you’re like, went through a divorce, but I’m totally good. And like everything’s totally fine. And like everything’s all right. for the people that are out there that would just be like, cool, see, he’s totally good. Like you’re actually hurting those people at that point. And it’s interesting, cause I think there’s a lot of like, there’s a lot of hurt that’s being given out from coaches because they’re not actually working through this stuff that they’re working through. You told me before we even got started, like you were doing the work and kind of almost tripped into this because it made sense to do it when it made sense instead of like where I think 2020 and the whole COVID thing is an easy thing to look back to because a lot of people were like, well, what the fuck do I do now? I guess I become a coach for what? I don’t fucking know. But I guess I’ll do it because I see these other people doing it and like, why the fuck not? And at that point, they’re just like spewing things. I kind of tripped backwards into coaching because I went through a divorce and I had friends that were like, man, you helped me. Can you help a buddy of mine who’s also going through shit? Can you help somebody else? And it’s like Damon Cart (11:46.635)Yeah. Nick McGowan (12:05.334)Yeah, but I need to do so much more work because the more that you learn, the more you understand. Like there’s more to know about it. And likewise, I’m sure with the NLP stuff, like as you started to go into it, I’m sure you got three weeks, three months, three years into it. You’re like, oh my God, there’s so much that I’ve learned from it that you’re then able to turn around. And it sounds like you’ve got a good, I guess mindset, a sense of like, I’m going to help. I want to deliver the information instead of like pushing it upon people. But why don’t we take a little bit of a step back. How the hell did you get here? I know a little bit of the story, but why don’t you share that? Because again, context is important. Damon Cart (12:40.153)Yeah, so I became, well, I had my first depression right after I graduated college and it was, 9-11 happened. It was the first time I was out of school in my entire life. I guess I started going to school like at three and now I’m like 22 and I’m out of school for the first time and just, you know, facing that the rest of your life. Like, what do I do now? Nick McGowan (13:06.409)Yeah. Damon Cart (13:06.734)Yeah, 9-11 happened, which really shook me up because you feel like you’re living, you don’t even question your safety and suddenly something like that happens. And then I got arrested for something really stupid. And it’s really stupid to the point where it’s like, I mean, if you want to get into it, I don’t mind talking about it, but it’s not, I don’t know, I don’t find it that relevant. anyway, those three things happened in one summer. And I just was like, I don’t even feel like walking out my front door. It just feels dangerous. Like, who knows what can happen? Nick McGowan (13:22.1)I’m down. Nick McGowan (13:26.206)Fair enough. Damon Cart (13:35.047)And I gradually just kind of like pulled in more and more and didn’t process the feelings, the negative feelings that I was experiencing. And I just suddenly I realized I’m in a really bad place. And I’ve actually been in this place for months now. And I don’t know how to get myself out of it. And I remembered that I had a professor who taught a class called the philosophy of psychology. And he went through different therapeutic modalities, including hypnosis and gestalt therapy, which NLP is based on. And then at the end, he Nick McGowan (13:57.267)Mm. Damon Cart (14:04.856)pulled out NLP and he said like, this is the mother of them all, because it takes the best of everything that whatever works. And I was just amazed by what this guy could do. And I was, I remember thinking to myself, I got to learn this NLP thing one day. So that was in college and then I was graduated. Now I’m experiencing depression. I don’t have health insurance. I’m a bartender. And so I can’t, I don’t even have the money to hire a therapist. Nick McGowan (14:16.2)Mm. Damon Cart (14:27.502)So I remembered my professor and I called him up and told him what was going on and he said, well, come into my office. He said, I don’t believe in a free service, but I also don’t need your money. So he said, donate your time every time you come to see me to charity or money or whatever. And he’s like, I’m not going to check back with you. I’m just going to trust that you do it. Come back next week and we’ll get to work. I come back next week and in one hour session, months of depression is gone. And I just, my logical mind said, no, no. Nick McGowan (14:45.971)That’s cool. Damon Cart (14:57.056)No, cannot even be possible. But every other part of me was just like, I’m free, like I’m not depressed anymore. And I remember leaving his office and just like I had to stop and sit at a bench on the campus and was just like looking around. like, I walked in there a different person. I walked in there depressed and I’m walking out and there is no depression. just didn’t, it seemed crazy. And so I didn’t get depressed for another 10 years. And when I finally got depressed again, it had nothing to do with what I had gotten depressed with the first time. Nick McGowan (14:58.13)Hehehehe Nick McGowan (15:19.816)Yeah. Damon Cart (15:26.926)But I can say now, knowing NLP, that it was a way that I would think about things. Depression is a process, not like a thing. So, you know, 10 years later, now I’m living in Santa Cruz, California. I have an insurance agency. I’m married and I have two really young kids, like two kids under two years old. And everything is going wrong. And so I slip into a depression again and then even realize it. My wife at the time, ex-wife now, she’s a therapist and she just said, you need help. And I remember Part of me was like well, no, don’t and then I just stopped and I was like, yeah, actually I do I’m not good. And so I found a therapist and this was traditional therapy So I went to traditional psychotherapy and it took me an entire year to come out of depression So we’re talking one session with somebody who knew NLP versus an entire year with someone who’s doing more traditional therapy And when I started to realize even though I was out of that depression I was thinking maybe I can make some progress and some advances here But no, he only knew how to get, this therapist only knew how to get you out of the hole. And then once you were there, then he kind of like kept you there by asking more and more about problems rather than trying to move you to solutions. And I was like, okay, this isn’t working for me anymore. And so I stopped going to see him, but I knew if I didn’t do something different, I was going to end up right back there again. And that’s when I decided it’s time to learn NLP. And there was a training that might still happen here in Santa Cruz where NLP was created up at the university every summer. Nick McGowan (16:31.538)Mm. Damon Cart (16:56.52)And so I went to that training and it just felt like I came home. I was like, this is what I’ve been looking for. And I wasn’t even thinking that I was going to be a teacher or a coach at that point. I was still thinking I’m going to fix my insurance agency and I’m going to fix my marriage and everything’s going to be great. And I just couldn’t stop doing NLP. I would just try to get into a training every chance that I could. Like I mentioned before, I was practicing all the time. And by the time I came back a year later, Nick McGowan (17:00.627)Hmm. Damon Cart (17:22.79)About 75 % of the people who were there the year before returned for the, it was a master practitioner training. And they just kept coming up to me and they were like, why are you so much better than us? And I was like, I don’t know. said, so I started asking them questions and they were like, you we went, we got the same certification you did. So we, you know, we should be at the same level as you. And I was like, did you practice? Have you practiced at all since the last training a year ago? And they were all no. Nick McGowan (17:28.528)Well. Damon Cart (17:51.343)I was like, it’s not a secret. If you don’t practice, you’re not going to get good at it. And that’s why I’m better than you is I’m not, I don’t have any special talents. just practice. And, uh, so, and that’s when people started saying, uh, and then when I go to other NLP trainings, people would be like, well, how long have you been a coach or how long have you been a teacher? And I was like, I’m not, I’m an insurance agent. And they were like, what are you doing here? Cause mostly coaches and you know, teachers go to these trainings. And, uh, so yeah, by that point, after a year had passed, I was like, yes, I’m going to. Nick McGowan (17:53.212)Yeah. Damon Cart (18:20.216)I’m coaching, I’m gonna do teaching. And even still, was more about I wanted to be better at NLP and that was was driving me to wanna do that. So I started just teaching workshops and when that didn’t go very far, that’s when I decided to get on YouTube. A friend of mine actually said, hey, you’ve been to film school, why don’t you try YouTube? And so like, okay, I’ll give that a shot and I did. And yeah, I realized in that whole process that my marriage was not salvageable. was… just, you know, we hit that inroads and it was nothing that was going to make it better. And I also realized that being an insurance agent was making me absolutely miserable and there was no changing that. So it was like, you know, it’s not, I always thought that it was something about me not being good enough. And that’s why I wasn’t succeeding at the insurance business, but it was like, no, it’s just not a good fit. The crazy thing about it, once I realized that, and I realized that it was just going to use the business to keep me afloat until I transferred into this other business. I actually was able to make it successful at that point. was really strange. It’s like when, you know, this thing you’re trying so hard to do and then you finally say, fuck it, I don’t care anymore. Then it, you know, then it was easy. And then it was like, I want to say it easy, but it was, it was working a lot better. And so I was just basically, I moved my office in with another agent. said, can you babysit this while I transition out of this? And he said, yeah, absolutely. And so I was, you know, it took me a few years to kind of figure out this new business. But once I did, I was, I jumped and haven’t looked back since. Nick McGowan (19:20.817)the Yeah. Nick McGowan (19:46.162)I love all that and especially the I mean the real side of it like I joked like yeah You were overnight success took nine years like the amount of stuff that people see that they think like this is Whatever they make it up to be in their own heads and the fact that you were doing the work I mean there are little principles that are through all of this stuff where it’s like You did it in the sense that you just wanted to learn it and you were you even said to me that it was your calling When we feel that and we go in that direction, things will start to get easier, even if it’s the other stuff of like, I need to get this away. And I don’t know the answer to this question, but is it safe to assume that you’re living a better life and more happy life than you did when you had the agency, when you were married, at least to her and like where things are now, is it better? Damon Cart (20:33.742)100 times over. Especially thinking back during the times that I was depressed and I was just like, I guess this is just kind of how life is going to be for the rest of it. And that was depressing to even think about. And that’s what I like to tell people because when I come across someone who’s either depressed or kind of close to that. I want to be respectful. You don’t want to just say, your life is so much better than you. That will make it worse. what I do want to communicate to them is it will get better. It can get better. If you’re adamant about being a happy and fulfilled person and you’re willing to work for it, you will get there. You’re not stuck. This is not how the rest of your life has to be. Nick McGowan (21:02.095)Yeah. Damon Cart (21:25.708)Because yeah, like at this point, it’s like it has exceeded the fulfillment I experienced now has exceeded what I thought was even possible. And still it’s getting more and more fulfilling. So my take on it now is just like, well, how, how good can this get? How deep can I take this? And it’s not like a, it’s not like a greedy thing. It’s more of like a potential thing. What potential do I have to be even more fulfilled and Nick McGowan (21:43.877)Yeah. Damon Cart (21:52.844)more engaged in life and I’m curious to see how far I can take that. Nick McGowan (21:58.124)What a cool aspect of it. Like, well, fuck, let’s see what happens. And like, cool, let’s see how far we can go. And I think to call something out here too, for the people that are listening, isn’t, Damon’s not saying like, well, I was in a shitty spot. I learned this thing and everything worked better. Like that’s just not how life works. Like the amount of work that you had to put in that wasn’t just like curriculum work, but also work on your own. if you… Damon Cart (22:01.698)Yeah. Nick McGowan (22:26.232)If you actually sat back and thought about the amount of hours that you spent just even pondering on it, thinking about it, looking at other people, how they relate to life and what they do. Like you literally enveloped yourself in it instead of saying, well, I really want that. And the reason why I say that is there are people that I hear from the times that are like, man, I’ve tried therapy. I’ve tried this. I’ve tried that. It’s like, great. So what’s next? I’m like, if that didn’t work or if that was a piece of it, like talk therapy, everybody will go into talk therapy and they’re like, This was great and it led me in some direction or it was bullshit and I just yammered to somebody about my problems and they were, they would ask me, how does that make you feel or whatever? It’s like, that’s a part of all of this, but not just the end thing. I think a lot of people do want, they just want that like, what’s the pill that I can swallow and like push all this stuff away instead of trying to break down one barrier to break down another, to break down another, like they’re. There are visuals in my head at times where I’ll climb a mountain only to get to the top of it and go, what the fuck is that? Jeez, it’s another, all right, cool. And you get to a point where you just, you keep trucking along with it. So let’s talk about some of the really tough times where obviously going through a divorce can be a tough time. And for somebody who’s a divorced, it’s one of those things like congratulations or I’m sorry, or a mixture of both, you know? But that can be one of those things that really shapes you in a beautiful way. Like I used to tell people, Damon Cart (23:44.2)All right. Nick McGowan (23:51.65)I didn’t get a divorce to die. I got a divorce so I could live and actually change things. like, I look at life now and think, my God, how did I have that same sort of question that you did of like, well, is this it? I guess this is it. So I guess this is just what life is gonna be like. And it doesn’t have to be that way, but there were still dark times he went through. So were there any that come to mind that you were like, man, that was one of those like super pivotal moments? Like I went through that within my NLP journey and that changed how things shifted. Damon Cart (24:23.212)Yeah, there were a few. When I got a divorce, I was dating for the first time in 15 years. And in my late 30s, that was scary. Things had changed quite a bit. Now there was online dating, and I tried that. And that didn’t go so well, because on these apps, it’s like 70 % men and 30 % women. So the odds are really stacked against you. So I also had my own business, so I wasn’t going to date my employees nor my insurance clients. so I started saying, realizing that I needed, if I saw an attractive woman, I was going to have to go and just talk to her, you know, and that was really difficult to do. And also wanted that choice because I was kept slipping in the relationships, even some of the rebound relationships that I went through, kept slipping in the relationships where the women would turn out to be very passive aggressive and playing a lot of games and really trying to control and manipulate me. And I remember coming to like a choice point thinking, wait, Nick McGowan (25:16.247)Mm. Damon Cart (25:23.126)Is this all women are all women like this or is this just the women I’m attracting? And so I had to be really like honest with myself and I was like, you know what? I’m going to take this on. This is my responsibility. I know that there are good women out there. And so there’s something I’m doing that’s attracting this type of woman. And I want to figure out what that is. And so I just decided I was going to just date and date and date for an entire year. And at the end of that year, if I found someone that I was going to settle down with them. And I did find someone and it was coming up to that year and then the red flag went up and I saw she was doing the same thing. And I was like, oh man, I spent a year doing this and I almost missed it again, almost got slipped into this relationship with this person who was basically going to, it was going to be a rerun of all my relationships. And so was like, I need another year. And so I went another year and I dated a lot. could catch these red flags very quickly. Nick McGowan (26:01.954)Hmm. Damon Cart (26:16.366)And I started realizing that I was putting a certain kind of vulnerability out too early and certain women, was attracting certain women because they thought that they could control me. But once I made it clear that I understood what they were doing, because the last thing a passive aggressive person wants is to be called out. That’s why it’s passive aggressive, right? So I would start calling out what they were doing. They would disappear very quickly. And then I started to develop myself along that way and started attracting much better women. But I do remember like, I was getting to the end of like, Nick McGowan (26:24.066)Yeah. Nick McGowan (26:30.517)Yeah. Damon Cart (26:46.178)I was getting into the third year and I was like, I’m not really finding anyone. was just, I was really getting a bit cynical about it. And I just thought maybe I’m not gonna find someone to share the rest of my life with. And so I quit dating for six months. Like I quit approaching, quit dating. And I was just like, I really needed to focus on my business. Cause that was something that was lacking as well. And I had another big failure in that. Nick McGowan (26:51.243)Hmm. Damon Cart (27:11.756)that I was able to overcome. I was like, you know, less dating, more attention on my business. And that started to work out well for me. And six months later, I had like zero social life. I hadn’t been on a date in, you know, six months. And I was like, OK, I was just finishing up this online training that I had created. I was like, I really need to get out. I need some sunlight. I need some fresh air and I need to see people. And I’m walking down the street downtown here in Santa Cruz. And I just see this really attractive. really young woman and I was trying to talk myself out of talking to her but I was like you know actually no I’m gonna go do this and I just walked up to her and told her I thought you know she was really cute and that I wanted to know her name and possibly go out on a date with her now I’m married to her and you think about those times where you know you almost didn’t do something but you did and then how that changes the trajectory of your life And then that opened a whole new can of worms because she’s from a different country and we got separated by COVID. And she also got her visa taken away. we basically, we eloped in Istanbul, Turkey. The media picked it up and so it was broadcast live in Turkey, our wedding. And then we still couldn’t be together. And so it went on for two more years where the only way we could be together is if I traveled to Romania or we traveled to a country where we could both enter. It was a… Nick McGowan (28:37.42)Mm. Damon Cart (28:38.508)That was another dark time, but with a light at the end of the tunnel. but yeah, that’s, I threw a lot in there all at once. And I also, another dark time was a time that, I, my, business that I have now, had a major failure. And I just thought that was the end of it. All this work that I had done on YouTube for, you a year of doing videos. did a video every single day for eight months straight. And that was a lot of work. And I, that’s how I started to build. Nick McGowan (28:45.366)pain. Damon Cart (29:07.232)my following and then I put out my first training after doing youtube and it just was a spectacular failure and I thought that’s the end of it all this work that I had done and six weeks of I didn’t publish a single video and for six weeks and then suddenly I started getting all these emails and these messages hey we haven’t seen you put a video out in a while we’re worried about you are you sick are you dead let us know you’re okay and I was like you wouldn’t come to my Nick McGowan (29:30.154)Thank What? Yeah. Damon Cart (29:35.235)fucking training and you just want me to keep putting free videos out there. Is that what this is about? So was a little resentful, but then I started making videos again. And then I realized what that was all about. It was, I was promoting a live in-person workshop for a different trainer. And it was like, they, my following didn’t know who he was and didn’t want to see him and didn’t want to show up to a live workshop. They wanted on, they found me on a screen. They wanted me and they wanted me on a screen. And that’s when I realized. Nick McGowan (29:41.654)Yeah. Damon Cart (30:02.734)that they wanted digital products, digital trainings. And so I didn’t know that at the time, but I just thought nobody really wants to know what I have to say and that’s the end of it and it’s time to go move on to a different business. It was quite a relief when I realized the mistakes that I’d made and that actually people did want what I was offering. yeah, so it was a interesting learning curve and very frustrating at the time, but it all ended up being really good. Nick McGowan (30:31.084)So in what was that five minutes seven minutes, maybe you’ve just chunked all this stuff in and I I laugh at times because I think it’s funny how we can we can look in like history books and they’re like from this period to this period like 600 years these three things happened. What the fuck do you mean? Like there were so many other things that happened. You had all these dark times even the six weeks off. I’m sure you still had the body feeling of like why I got to sit down. I could do the video. Wait a minute. And then people come back, be like, are you all right? Are you dead? And be like, what the fuck do you mean? Where have you been? And you’re like… Damon Cart (31:04.15)No, and was so cliche, like whenever that failure happened, had trouble getting out of bed. I stayed in my pajamas most of the day. All the blinds were closed. They had very little light in my apartment. it’s like, because it was so weird. Like, I look back on it now, but it was like, that’s what you would see in a movie because you have to like show, you know, what’s going on inside the character by lighting it the right way and all that. And it was like, that’s what I was actually living through. And I didn’t even realize it at the time, but I was like, yeah, it was a Nick McGowan (31:24.479)Yeah. Damon Cart (31:33.773)It was a dark time and it was literally dark in my home. And that’s the way that it all felt. And finally, I remember just kind of emerging from that. And it was almost like opening the blinds and letting the sunlight in. it was like, you know what, I’m going to pick up my camera. And, yeah, I was just like, you know what? I’m a teacher. This is what I do. So I’m going to put that camera back up and start teaching again. And then eventually shortly thereafter, it led to one of the biggest successes that I had that still creating a training that I’m. Nick McGowan (31:37.685)Yeah. Nick McGowan (31:45.215)Bird singing. Damon Cart (32:02.956)you know, still selling to this day because I put so much effort into it. And, but if it hadn’t been for that failure, I would have never discovered that. And so, you know, it’s how these things often work. Nick McGowan (32:14.994)It’s how life works. Like you have to fail through things. You have to fuck around and find out. You also have to bash your head into the wall, the wrong wall sometimes to go, well, shit, that’s the wrong direction. Let me go back. And you still can learn things from it. I think, I think we can sometimes understand, from an intellectual perspective, like, yes, I get that you need to fail. You need to do this to do that. But then when people get into it can be really, it can be hurtful in a way that isn’t just to the timing that they’re in, but there are so many other things that they haven’t worked through or processed through that it feels like they’re just stacking it on. Like, and now this, and now that, and my God, and now my shoes, and now this. It’s like, you’re just adding things to it. But it can be really easy to do that when you’re in that dark spot. Now, obviously you’ve been through these different things. You’ve fucked around, found out, but you’ve also learned through all this stuff. And I joke with the like, well, here was this short little thing. Like how they even do it in movies. Like all this chaos and craziness happened and like 15 minutes later, it’s like, no, there was a lot of dark times, but there’s still that momentum and that movement. Even if you’re slowing down and you’re resting, you’re still moving in that direction. So the fact that you just didn’t give up, like, let’s be real, man, you had a lot of different times you could have just totally checked out. You could have been like, no, this is too much. I’m not doing it. And now, like, have you thought about that? Like, what have you checked out? You wouldn’t be where you’re at. You wouldn’t be doing what you’re doing. You know, maybe you’re selling insurance again and like, fuck this, I can’t. Damon Cart (33:47.039)And I, you know, when I had that major failure, that’s what I thought. I was like, okay, do I have to go back into insurance? And I was seriously considering that. And, man, it was so painful to just even think about that. what I see with a lot of people, the real difference between people who are living the life that they want to live and really fulfilled by that and experiencing the kind of freedom they want is… They stuck with what they were doing, even if that like evolved, you know, because you try things, they fail, you keep trying new things. And so it evolves, but you’re still sticking with it. And what I would say is, you know, the really important thing is not to be so fixated on how you’re going to get there because I, if I had actually gotten what I wanted the way that I thought I wanted it, it would have been a lot more restrictive. I would have been having to show up, you know, just to keep my money going out, to actually physically show up in many different places and be teaching constantly, which is, you know, that’s what my teachers were doing. So I thought, well, that’s how it’s done. But they hadn’t really tapped into the Internet and YouTube and all that. So now I get the choice if I want to do that. I don’t have to like do that all the time. So I learned enough about, you know, business and everything to make it work the way that I make it work now. But that only came because the way that I thought I was going to do it failed miserably. So had to try to had to find a new way. Nick McGowan (35:06.633)Hmm. Damon Cart (35:08.192)When I think about like, had this weird experience earlier this year, was, so my wife and I, also my wife’s Romanian and we have a home in Romania. So we always go there in January and then we went to Cambodia and then we went to Vietnam. And I remember just like it really hitting me how much I was driven by freedom. And this is another thing that I think is really important to understand is when you, when you focus on values, then you’re not so focused on how you think it has to happen. You become more flexible and you know what. the values are that you’re after. And for a long time, freedom was such an important thing to me. And I remember earlier this year being in Vietnam and just being like, more freedom is not going to make me happier. More freedom is not going to make me more fulfilled. I have really hit that level of freedom that was far more than I expected to ever achieve. I can travel anywhere and go anywhere because I can run my business off of a laptop. And also have a great team of people who I work with who, you know, I don’t have to do everything. Nick McGowan (35:50.761)you Damon Cart (36:07.598)They’re there for that as well. So I have the money I need and I have all the freedom to travel and do whatever. And that was both a victory in that moment that I realized that, but it was also like, okay, so where do I go from here? And it was like a real question for me to sort of contemplate. And that’s, I that might sound a little arrogant, like you achieve all that you want and then you’re kind of like, okay, well, what do I do now? Like that’s a… a first world problem that most people would want to have that don’t even get to that point to have. it’s be prepared for that. Like if you really believe you’re going to be successful and you’re not going to stop until you become successful, be prepared for those moments that you have where you go, wow, OK, I really have it now. What now? And so I thought about all these different things that I could do from that point on. And I was like, well, wait a minute. It’s not about doing something different. I’m so happy with what I’m doing now. I don’t need to do anything different. I just want to do more of what I’m already doing. Nick McGowan (37:05.094)Yeah. Damon Cart (37:05.26)and I don’t need more freedom to do that. And it was a realization of I don’t need to be pursuing freedom so hard anymore because more of it actually can, at this point in my life, would probably be more nihilistic or more escapism. And it’s like, that’s not worth that either because that’s not gonna fulfill me more. So it was an interesting realization to come to that. And it’s like, yeah, okay, freedom doesn’t have to be the main thing here anymore. Nick McGowan (37:22.481)Mm-hmm Nick McGowan (37:33.874)Well, I think we’re also taught in this world with all the systems we have that you have to have a destination. Like think about even being like in high school and they’re like, we, need a five or you need a 10 year plan. That was always so difficult. I remember somebody even years ago was like, well, what’s your five or 10 year plan from now? It’s like, fuck if I know, because anything I come up with is going to be like half-hearted and like what I kind of want right now. But as you’ve moved through things and you do things, you start to see, well, I really want this. I want that. Like freedom is a big thing. I think a lot of people want freedom. I. Damon Cart (37:43.822)Hmm. Hmm. Nick McGowan (38:03.706)I love the freedom that I have. I’m right there with you where it’s like one of those things where you go, well, cool, I have it. Well, that’s cool. But like what’s really fulfilling inside is the thing that actually just drives us and pulls us from basically our chest. So for the people that are on their path towards self mastery and with everything you’ve gone through and especially with NLP, what’s your advice for those folks? Damon Cart (38:26.318)Keep your attention on what’s most important and what’s most important is your values. A value is a generalization about an experience that is important to you. So if happiness is important to you, success is important to you, authenticity is important to you, always keep your eyes on that. And then any goals you set need to be aligned with those values. Most of the time people have no idea what their values are in a particular context and they will be different from context to context. And they just set a goal because they think, okay, like you said, You have to have a destination, right? So here I’m going to set this goal, but they don’t really understand what’s driving the motivation to have that goal. And a lot of times it’s more external values. Well, other people value achieving this, so it must be valuable. Or if I achieve it, then these people will think very highly of me and respect me. Those are, you know, if you’re accomplishing something that does those things, there’s nothing wrong with that. But if that’s why you’re doing it, you’re probably not going to be fulfilled. by accomplishing that. And so a lot of people are chasing goals that are not even fulfilling to them. And whenever they fail at that, because really there’s that inner wisdom that is holding them back, like the inner wisdom that helped me back from succeeding as an insurance agent, because that would have been the golden handcuffs. It would have been really hard to walk away from a very successful business with a lot of money. And I would have probably tolerated that misery. you want to be careful. know, like when you quit at something because you run out of motivation for it. Nick McGowan (39:45.318)Hmm. Damon Cart (39:52.345)Check in with that is that a deeper wisdom that knows better that that’s not really going to fulfill you. But what most people do is they beat themselves up and they say, I should have had more discipline or I should have had more willpower. I’m just not good enough. And they go into this whole self-worth thing, which is not real by the way. It’s something that holds a lot of people back. And then the people who do succeed at it and they get there and they go, wow, this isn’t fulfilling. This feels rather empty. thought it would be great if when I finally Nick McGowan (40:03.791)Yeah. Nick McGowan (40:08.454)the Damon Cart (40:21.39)Achieve this but again, it wasn’t aligned with their values. So no, it’s not going to be fulfilling and Because they feel lost without a goal They set another goal and get back on that treadmill and they do the whole thing over and over again and people come to me for coaching now who are very very successful on paper you would think they would be extremely happy and fulfilled they have all the money they have the family they have the cars the house and everything and they’re coming to me because they feel like imposters or they’re coming to me because they feel so unfulfilled and they can’t understand it because they’ve accomplished everything they’ve ever wanted to accomplish yet they feel so empty inside. And it’s like, yeah, you’re good at accomplishing. The problem was you never really got in touch with what do you truly value? What is really important to you? And so that’s the most important thing is what’s most important to you. And the better you understand that, the more clarity you have around that, the more you’re naturally going to be drawn to that and motivated to do that. The other thing I would say is There is no such thing as self-worth. How this problem comes up is feeling like you’re not good enough, feeling like you deserve it or don’t deserve it. It goes both ways. And so what most people are feeling is a low sense of self-worth. And they feel like if I go and try to achieve something and I fail at it, I will lower my self-worth and I’m already clinging to what little I have. So most of the time people won’t do something and they’ll sit back and say, well, I’m waiting for the right opportunity. what they’re waiting is to feel of higher self-worth so that they feel like they can go do something and if they lose some self-worth, they’ll still be okay. Well, here’s the thing, there is no such thing as self-worth. There is no way to measure your value, which is what worth is. It’s really a metaphor and there’s a lot of problems that happen when we try to apply metaphors literally. And we see this in the Bible. Fundamentalists are people who are trying to apply metaphors in the Bible literally and it causes a lot of problems. So what people do is they have this idea of self-worth. And so they think, well, how do I measure my worth? Well, first of all, there’s no way to do it. There’s no objective scale or person who can be objective and measure people’s worth. So what do we do? We compare ourselves to others and that will destroy you every time. If you compare yourself to others to make yourself feel better about yourself because you think they’re less than you. Now you’re engaging in the superiority that’s going to bring you down. And if you play that game, you can’t only play it in one direction. Damon Cart (42:45.87)when you encounter someone you think is of higher worth than you, now you’re gonna feel bad about yourself. The whole thing, you can kill the whole thing just by stop comparing yourself to others. Now this idea of self-worth, it usually comes about very early in life and we just pile more and more beliefs on top of that whole idea. So the two things that I would recommend is get clear and clear about your values, basically what’s important to you. What does that actually look like to you? And you’re not going have it all figured out. And you’re definitely not going to figure it out all out on paper. You need to take action. And action is the best way to get that clarity, experience. And then the other thing is to dismantle the whole concept of self-worth entirely. When you do that, when you do those two things together, you’re just on the path to living a very fulfilling life, a life of being who you want to be and therefore creating the life you want to live. Nick McGowan (43:38.213)That’s awesome. And I think a lot of people can anchor into like the understanding of action and motivation too. Like you have to take action to be motivated, continue to do the thing. It’s likewise with what you’re saying where you have to take those actions, but you have to understand why you’re doing those things. And it is interesting how a lot of people don’t know what their principles are or they are somebody else’s principles. Like, well, my wife and I, or my partner and I, or my family and I, have these principles. Like, well, where did those come from? Well, you know, they just kind of came up and like, we don’t really think about that or don’t think about it throughout their day to day life of like, well, how do I move about this? And why do I want to do such a thing? I’m really glad that you touched on those two things, man. It’s been great having you on. So I appreciate your time. Before I let you go, where can people find you and where can they connect with you? Damon Cart (44:27.852)Yeah, the easiest place is my YouTube channel. It’s just Damon Cart, Damon Cart NLP. And we’ve got a lot of videos been doing this for quite a while, almost 10 years. So that’s, you’ll find not only my videos, but in my videos, I give a lot of free resources so that you can get started usually on the topic that I’m giving you or the solution to a problem. You can access like free PDFs and things like that. so also I have my website is selfconcept.com. Like I said, I do general NLP, but I also really focus on this one model because your beliefs about yourself determine your beliefs about everything else, you the world around you. And if you haven’t realized already, it’s your beliefs that govern your reality. So what you believe is possible, what you believe is true. lot of, most of our beliefs are deeply unconscious. So when you can understand what the beliefs are, especially the deeply unconscious ones about who you are, when you understand what those are, you understand their limitations and then you transform them so they don’t have those limitations. Then you become that person you value. Your self-esteem goes up, your confidence goes up and you naturally gravitate toward creating that life that you want to live that’s reflective of the value that you are. Nick McGowan (45:45.38)So wait, you putting worth to that? No, I’m just kidding. I’m only kidding. Awesome, man. Well, again, I appreciate your time. Thank you so much for being with us today. Damon Cart (45:48.052)It’s different, worse than the measurement. Damon Cart (45:55.246)Thank you for having me on.

In this week's episode, Blood editor Dr. Laurie Sehn interviews three of the latest Blood authors: Drs. Vijay Sankaran, Ruud Delwel, Françoise Kraeber-Bodere. Two studies on the MECOM gene have been paired in this episode, analyzing new groundwork for potential novel myeloid differentiation therapies via repression of MECOM restoring enhancer mediated CEBPA expression. We'll also hear about the results of CASSIOPET, imaging companion study of the CASSIOPEIA trial, and how achieving negativity in PET before starting maintenance therapy is significant even in patients who still show residual disease in the bone marrow.Featured ArticlesCEBPA repression by MECOM blocks differentiation to drive aggressive leukemiasMECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed from the CASSIOPEIA trial

Networking não é sobre cartões de visita. É sobre criar pontos e manter o capital relacional em circulação. No palco do FROTA Summit 2025, Pedro Waengertner traz uma nova perspectiva sobre como cultivar conexões genuínas em tempos de excesso de tecnologia e escassez de atenção.Mesmo sendo introvertido, Pedro construiu sua trajetória com base em redes diversas e mostra, com histórias reais, como o valor das conexões está mais em como nos relacionamos do que em quantos contatos temos. Ele fala sobre o poder dos laços fracos, a importância de combinar mundos diferentes e a arte de ser útil antes de ser lembrado.Também discutimos:Por que a automação esvazia o valor das conexões digitaisComo pequenas ações criam grandes oportunidades no futuroE por que manter sua rede ativa é tão importante quanto atualizar o currículoSe você acha que networking é forçado, ou não sabe por onde começar, este episódio pode mudar sua forma de enxergar (e cultivar) relações profissionais.Dá o play e vem com a gente!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving deep into the latest breakthroughs, regulatory updates, and industry trends shaping the future of healthcare.Let's start with Johnson & Johnson's recent achievement in precision oncology. They've secured a second FDA approval for Akeega, a combination therapy that merges J&J's Zytiga with GSK's Zejula. This innovative approach targets BRCA2-mutated metastatic castration-sensitive prostate cancer, marking a significant advancement in personalized medicine. This approval not only highlights the progress in tailored treatment strategies but also sets a new benchmark for therapeutic innovation in this particular cancer subset.Moving on to cardiovascular health, Cincinnati's LIB Therapeutics has introduced Lerochol, a third-generation PCSK9 inhibitor designed to lower cholesterol. Unlike its predecessors, Lerochol offers simplified administration, potentially improving patient adherence and outcomes. This approval is part of a broader effort to refine lipid-lowering therapies and better address cardiovascular diseases.In a groundbreaking development for heart rhythm disorders, Milestone Pharmaceuticals has received FDA approval for Cardamyst, a nasal spray that patients can self-administer to manage paroxysmal supraventricular tachycardia (PSVT). This novel treatment option empowers patients with an on-demand solution to control their heart rhythms, significantly enhancing their quality of life.Turning to infectious diseases, Innoviva's Nuzolvence has been approved as a much-needed new treatment for gonorrhea, the first in over three decades following GSK's Blujepa. This marks an essential step forward in combating antibiotic-resistant sexually transmitted infections and highlights the urgency of developing new antimicrobial agents.However, not all ventures have met with success. Argenx recently halted studies of its drug Vyvgart in thyroid eye disease after disappointing trial results. This decision underscores the inherent challenges and risks involved in drug development, particularly when tackling complex autoimmune conditions.Sanofi has faced its own hurdles with Tolebrutinib after experiencing both FDA delays and trial misses in non-relapsing secondary progressive multiple sclerosis. These setbacks emphasize the intricacies of bringing innovative therapies to market and the critical importance of robust clinical trial design and regulatory strategy.Strategic collaborations are also playing a pivotal role in the industry. Adaptive Biotechnologies has partnered with Pfizer to leverage its T-cell receptor discovery technology. Meanwhile, Dren Bio is expanding its collaboration with Sanofi to develop next-generation B-cell depleting therapies for autoimmune diseases. These alliances reflect an increasing trend towards collaborative innovation to harness cutting-edge technologies.Another strategic move comes from Sobi, which has acquired Arthrosi Therapeutics for $950 million to bolster its portfolio with phase 3 gout treatments. This acquisition bypasses traditional IPO routes and showcases evolving deal-making strategies within biopharma.In another exciting development, Kyverna Therapeutics is on the verge of securing the first-in-class CAR-T therapy approval for autoimmune diseases following promising trial results with its CD19 agent. This could herald a new era in autoimmune disease management through cellular therapies.In regulatory news beyond pharmaceuticals, former President Donald Trump signed an executive order establishing a unified federal framework for artificial intelligence (AI). This aims to streamline AI regulation across states and could accelerate AI integration into various sectors, including healthcare.These developments collectively represent pivotal moments in the pharmaceutical and Support the show

This month, the multitalented Tawny Platis joins the gals to tell stories of abstract art, an immersive job interview, Kim Crawford's betrayal, flying cornucopias, Mama Mia showdowns, a haunted footprint, and a woman who did not marry her brother. Tune in for December's episode of Gossip at the Corpse Cart! For more info on Tawny's many talents, go to https://tawnyvoice.com/ For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.  

Audio roundup of selected biopharma industry content from Scrip over the business week ended December 12, 2025. This week, a focus on five key results from the American Society of Hematology (ASH) meeting – Jaypirca headed for the front line; Kite's Anito-cel in multiple myeloma; next-generation CAR-T approaches; Kelownia's early in vivo CAR-T data; and Novartis's ianalumab's potential in ITP. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-RFOOY2665REEZEN5SMJ2GW27EY/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

durée : 00:03:28 - Les P'tits Bateaux - par : Camille Crosnier - Aujourd'hui, Adèle se demande pourquoi toutes les personnes n'ont pas la faculté de faire des acrobaties comme par exemple le grand écart, la roue ou le poirier ? La danseuse étoile Dorothée Gilbert lui répond. - invités : Dorothée Gilbert - Dorothée Gilbert : Danseuse étoile dans le Ballet de l'Opéra de Paris - réalisé par : Stéphanie TEXIER Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

The Golf Competence Achievement & Reward Test, otherwise known as the golf CART™, can help you put your year in perspective. Sam Weinman and Golf Digest social guru Will Irwin walk us through the process and share their scores. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Why did a DoorDash driver allegedly douse a food order in pepper spray, causing a customer to choke? Lionel unpacks the terrifying realities of modern delivery culture, from Amazon buggies to apartments acting as UPS stores. Then, it's a deep dive into culture and controversy: discussing the resurgence of traditional Latin Mass among young people and debating concepts of tradition, assimilation, and identity in America. Learn more about your ad choices. Visit megaphone.fm/adchoices

>>Take the 450th podcast episode player survey to enter into tons of awesome gifts! >>Read the holiday gift guides:  Best Golf Gifts in 2025  Best Golf Gifts for Men  Best Golf Gifts for Women  Luxury Golf Gifts  Best Golf Gifts for Kids  Best Golf Gifts Under $100 Today I'm sharing an episode where I was a guest on 2 Dudes, 1 Cart podcast. In this episode, we'll cover: Why you need a highlight reel How to overcome slumps faster than ever How the 8-second secret can transform your scores  The art of playing better under pressure and tournaments  And more strategies to play consistent golf using wicked smart strategies.  WICKED SMART GOLF Recommended Products Think Like a Pro with DECADE Golf: The #1 course management system to think like a pro (use code WICKEDSMART to save 20%). Speed Train With Rypstick: The #1 speed trainer to add 10+ yards in 40 days or less (use code WICKEDSMART to save 20%)  Master Mobility & Flexibility with Golf Forever: The best way to work on your golf fitness at home or the gym, with easy to follow plans & app (use code "WICKEDSMART" to save 15%).  Use HackMotion for Better Ballstriking: The best wrist trainer in golf and become your swing coach (use code WICKEDSMART to save 5% on your investment).  Wicked Smart Golf Academy To Lower Your HDCP Fast: The FASTEST way to play consistent golf.  Practice Like a Pro With Wicked Smart Golf Practice Formula: 75+ Practice plans and a 90-minute masterclass to practice like a pro.   Also, don't forget to connect on social media: Follow on TikTok Follow on Instagram   Subscribe on YouTube Read or listen to Wicked Smart Golf on Amazon or Audible (ideal for beginner to intermediate golfers who want 111 ways to play better without swing changes.  Read or listen to Wicked Smart Golf II on Amazon or Audible (perfect for golfers looking to break 80 consistently).  Read or listen to Wicked Smart Golf III on Amazon or Audible (best for players wanting to dominate competitive events).

CAR T-cell therapy is a potentially life-saving treatment for patients with certain hematologic malignancies. Yet, the logistical challenges and the need for specialized management of adverse events have limited its availability in community settings. In this episode, CANCER BUZZ speaks with Jeremy M. Pantin, MD, FACP, clinical director of the Adult Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, part of the Sarah Cannon Transplant and Cellular Therapy Network. Dr. Pantin discusses the cancer center's community-based, outpatient model, impact on outcomes for patients with hematologic malignancies, and shares his perspective on future changes needed to help further expand access to CAR T-cell therapy.     "Education of community oncology staff at their offices—coordinators, nurses, physicians, advanced practice providers—also goes a long way in helping facilitate patients to be recognized when they are candidates for cell therapy." - Jeremy M. Pantin, MD, FACP "It did not matter the distance to the center; did not matter the socioeconomic background. Many of the other factors one would think would lead to decreased access, we did not find among our centers. It was really the delay from consult to treatment." - Jeremy M. Pantin, MD, FACP    Guest:                  Jeremy M. Pantin, MD, FACP Clinical Director, Adult Transplant and Cellular Therapy Program Sarah Cannon Transplant and Cellular Therapy Network At TriStar Centennial Medical Center Nashville, TN   Resources: Bringing CAR T-Cell Therapies to Community Oncology   Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring   FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies

Radio Foot, deux émissions en direct ce mardi à 16h10 T.U. et 21h10 T.U. : - Ligue des Champions 6è journée, une 1ère salve de 9 matches parmi lesquels un alléchant duel entre l'Inter et Liverpool. ; - Monaco/Galatasaray. Les joueurs du Rocher dans l'obligation de l'emporter pour décrocher une place dans le top 16 où figurent les Turcs. ; - À suivre également : FC Barcelone/Francfort. Bergame/Chelsea. Ligue des Champions 6è journée, une 1ère salve de 9 matches parmi lesquels un alléchant duel entre l'Inter et Liverpool. Des Nerazzurri toujours candidats au titre, qui marquent beaucoup et feront face à des Reds en crise, qui encaissent beaucoup, et traversent une tempête médiatique provoquée par Mo Salah. L'Égyptien ne sera pas du voyage. Les Scousers n'ont remporté que 4 de leurs 15 derniers matches toutes compétitions confondues, comptent 3 succès pour 2 défaites dans la compétition. - Bayern/Sporting, les Bavarois pratiquement assurés de poursuivre l'aventure mais doivent renouer avec la victoire après le faux pas d'Arsenal. Les Lisboètes pointent à la 8è place et espèrent une qualification directe pour les 8ès de finale.   Monaco/Galatasaray. Les joueurs du Rocher dans l'obligation de l'emporter pour décrocher une place dans le top 16 où figurent les Turcs. Ils auront fort à faire face à Jakobs, Gündogan, Sané et Osimhen. Retour de Pogba en Ligue des Champions, du temps de jeu pour le milieu international ? - Réagir après la défaite de Lille. C'est l'objectif de l'OM, mais attention à l'Union Saint Gilloise, champion de Belgique. Une équipe joueuse et compétitive, mais qui n'évoluera pas dans son stade.   À suivre également : FC Barcelone/Francfort. Leaders de Liga, les Catalans doivent se reprendre après la déconvenue de Chelsea. Avec un point en quatre rencontres, les Aigles doivent faire un résultat au Camp Nou. - Bergame/Chelsea, match crucial pour les 2 équipes. Une Dea irrégulière face à des Blues privés de Cole Palmer, qui veulent figurer dans le top 8. Avec Olivier Pron : Nicolas Vilas, Nabil Djellit, Bruno Constant et Thomas de Saint-Léger à Monaco. Technique/réalisation : Laurent Salerno - Pierre Guérin.

Fueled by cancer, obesity and cardiovascular deals, $1 billion-plus takeouts in biotech are at their highest level in a decade with three weeks to go in the year. On the latest BioCentury This Week, BioCentury's analysts discuss the rise in large M&A deals and what the trends among the 37 acquisitions say about biopharma dealmaking.The analysts assess first-in-human in vivo CAR T data at the American Society of Hematology meeting from Kelonia Therapeutics, which showcase the promise of the modality and justify the growing pipeline. They also break down readouts from Praxis in developmental and epileptic encephalopathy from the American Epilepsy Society Annual Meeting and from Novo Nordisk, which presented full data at the Clinical Trials on Alzheimer's Disease meeting on semaglutide's failure to treat Alzheimer's disease.Washington Editor Steve Usdin analyzes a roller-coaster week at FDA in which Richard Pazdur resigned as director of FDA's Center for Drug Evaluation and Research and Tracy Beth Høeg became acting CDER director, a move that Usdin says will prompt staff departures, ease restraints on FDA leadersView full story: https://www.biocentury.com/article/657781#BiotechMA #CARTTherapy #EpilepsyResearch #AlzheimersDisease #FDA02:37 - Biotech M&A06:39 - In vivo CAR T10:08 - Semaglutide for Alzheimer's16:17 - Praxis22:11 - FDATo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Radio Foot, deux émissions en direct ce mardi à 16h10 T.U. et 21h10 T.U. : - Ligue des Champions 6è journée, une 1ère salve de 9 matches parmi lesquels un alléchant duel entre l'Inter et Liverpool. ; - Monaco/Galatasaray. Les joueurs du Rocher dans l'obligation de l'emporter pour décrocher une place dans le top 16 où figurent les Turcs. ; - À suivre également : FC Barcelone/Francfort. Bergame/Chelsea. Ligue des Champions 6è journée, une 1ère salve de 9 matches parmi lesquels un alléchant duel entre l'Inter et Liverpool. Des Nerazzurri toujours candidats au titre, qui marquent beaucoup et feront face à des Reds en crise, qui encaissent beaucoup, et traversent une tempête médiatique provoquée par Mo Salah. L'Égyptien ne sera pas du voyage. Les Scousers n'ont remporté que 4 de leurs 15 derniers matches toutes compétitions confondues, comptent 3 succès pour 2 défaites dans la compétition. - Bayern/Sporting, les Bavarois pratiquement assurés de poursuivre l'aventure mais doivent renouer avec la victoire après le faux pas d'Arsenal. Les Lisboètes pointent à la 8è place et espèrent une qualification directe pour les 8ès de finale.   Monaco/Galatasaray. Les joueurs du Rocher dans l'obligation de l'emporter pour décrocher une place dans le top 16 où figurent les Turcs. Ils auront fort à faire face à Jakobs, Gündogan, Sané et Osimhen. Retour de Pogba en Ligue des Champions, du temps de jeu pour le milieu international ? - Réagir après la défaite de Lille. C'est l'objectif de l'OM, mais attention à l'Union Saint Gilloise, champion de Belgique. Une équipe joueuse et compétitive, mais qui n'évoluera pas dans son stade.   À suivre également : FC Barcelone/Francfort. Leaders de Liga, les Catalans doivent se reprendre après la déconvenue de Chelsea. Avec un point en quatre rencontres, les Aigles doivent faire un résultat au Camp Nou. - Bergame/Chelsea, match crucial pour les 2 équipes. Une Dea irrégulière face à des Blues privés de Cole Palmer, qui veulent figurer dans le top 8. Avec Olivier Pron : Nicolas Vilas, Nabil Djellit, Bruno Constant et Thomas de Saint-Léger à Monaco. Technique/réalisation : Laurent Salerno - Pierre Guérin.

Pressure doesn't look dangerous—until the instant it is. We take you right to the two moments that matter most in filter service—when the lid comes off and when it goes back on—and show you how to turn a risky task into a safe, repeatable routine.We start by reframing the filter as a pressure vessel, not a harmless canister. Sand filters are usually one-piece and lower risk; cartridge and DE filters come apart, rely on clamps or locking rings, and can fail if misaligned or under-tightened. You'll hear why modern safety designs like the Aquastar Pipeline's interlock are so effective and how to apply the same logic on any system: power down, bleed air, drain, and verify zero pressure before loosening hardware.From there, we share practical safeguards that work in the field. Put automation in service mode, move Intermatic trippers, or cut the subpanel, but don't stop there—remove the pump lid so the system can't prime even if a glitch starts the motor. We talk through clamps in detail: reading spring-barrel nuts, preventing cross-threading with a touch of lube, knowing when a clamp is cosmetic-ugly yet structurally sound, and when to replace hardware for peace of mind. On restart, we step back, open the air relief, and wait for water before approaching. A spiking gauge is your red flag for a blocked return or a clogged salt cell; shut down fast, clear the path, and protect the tank.• treating the filter as a pressure hazard• relative risks of sand, cartridge, and DE filters• turning off power and automation service mode• removing the pump lid as a fail-safe• bleeding air and safe startup distance• clamp types, tightening until spring coils meet• avoiding cross-threading and when to replace clamps• spotting dangerous pressure spikes and return blockages• quick priming tips and avoiding automation glitches• training techs to follow a standard safety checklistLearn more at swimmingpoollearning.com  On the banner, there's a podcast icon—click for the archive  Learn more at PoolGuyCoachinSend us a textSupport the Pool Guy Podcast Show Sponsors! HASA https://bit.ly/HASAThe Bottom Feeder. Save $100 with Code: DVB100https://store.thebottomfeeder.com/Try Skimmer FREE for 30 days:https://getskimmer.com/poolguy Get UPA Liability Insurance $64 a month! https://forms.gle/F9YoTWNQ8WnvT4QBAPool Guy Coaching: https://bit.ly/40wFE6y

Taken as a group, blood cancers are the fifth most common type of cancer in New Zealand - affecting around one in twenty people during their lifetime. But some patients are forced to seek help overseas because a treatment that could save them isn't available here. The Wellington based Malaghan Institute of Medical Research is working to change that. Winner of this year's Breakthrough Project category in the KiwiNet Awards, Malaghan is currently conducting phase two of its CAR-T cell therapy clinical trials. The therapy essentially uses the body's own immune system to target and kill cancer cells. Professor Robert Weinkove is the Clinical Director and he speaks to Mihi about the next major step in their push to make it a standard part of cancer care in New Zealand.

Aaron & Tom review the state of the holiday retail climate, the history of America's vapor economics, the CNN x Kalshi collab, and financing Air Jordans at 22% interest. Subscribe to our patreon today: https://www.patreon.com/trillbillyworkersparty

Live from the Amazon Warehouse in Robbinsville, in this episode of The Speed of Culture podcast, Matt Britton speaks with Amanda Doerr, Vice President of Core Shopping at Amazon, for a deep and practical look at how Amazon AI shopping is reshaping the entire buying journey. From the launch of Rufus AI shopping assistant and breakthroughs in AI review summarization to the rise of conversational commerce, voice commerce, and mobile-first e-commerce, Amanda shares how Amazon is solving customer friction and building the foundation for the future of e-commerce 2026.Follow Suzy on Twitter: @AskSuzyBizFollow Amanda Doerr on LinkedInSubscribe to The Speed of Culture on your favorite podcast platform.And if you have a question or suggestions for the show, send us an email at suzy@suzy.com Hosted on Acast. See acast.com/privacy for more information.

Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi. In this final episode of this series, you'll meet Jan Janisch-Hanzlik. Jan lives with MS and is a participant in one of the clinical trials evaluating the safety and efficacy of CAR-T cell therapy for MS.  In CAR-T cell therapy, blood is taken from the patient or a healthy donor, much as you would donate blood. This blood is sent to a lab, where the white blood cells, or T-cells, are separated out and reprogrammed to carry a receptor designed to fight a particular condition. This receptor is known as a chimeric antigen receptor, or CAR. Over several weeks in the lab, these fortified T-cells multiply until there are millions of them, then they're reintroduced to the patient by intravenous infusion. CAR-T cell therapy is already used to treat some blood cancers, and Jan is the first person in the world to receive this one-and-done treatment to treat MS. She's joining us to share her experience participating in the clinical trial and to give us an update on how she's doing following her treatment.  This special episode of RealTalk MS is made possible by a generous grant from Sanofi. Sanofi has two ongoing Phase 3 clinical trials in MS studying Frexalimab, an investigational second-generation anti-CD40 ligand monoclonal antibody. If you are interested in learning more about these clinical trials, please visit SanofiStudies.com SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/ct4 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! Privacy Policy

Many see Amazon as a reliable source of consumer goods from toilet paper to wireless headphones. But Sean McLain reports that the “everything store” is now betting that consumers will also pick up much bigger items when given the opportunity. Plus, Imani Moise reports on why fintech company Block is sharing its version of a credit store with customers. Patrick Coffee hosts. Sign up for the WSJ's free Technology newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

God is asking you to follow him in a way that will require your faith. You're not going to understand it. You're not going to be in control of it. Can your mind make peace with the unknown? Can your hands remain open in full surrender? And girl, will your feet move forward to destination […]

Santa, baby! We're here to deliver the #damngood gifts of the season that the beauty lover on your list will *actually* want - no snoozefest presents in sight. Watch, and subscribe to this episode on YouTube! You'll hear about:The makeup musts we're swooning over (a luxury blush trio, lip gloss “stacks,” and a palette fit for Celine Dion)A makeup-meets-indie jewellery collab that's sure to spark conversation at any holiday party A chic AF bar soap gift set that's giving us major flashbacks to a coveted childhood stocking stufferThe high quality hair clips that not only hold up the thickest hair, but that are also the hottest style accessory of the season A French-girl approved advent calendar that doesn't skimp out on beauty goodiesA limited edition version of a 100-year old fragrance that's been updated for the vanilla lover on your list! (And the insider tip for how you can personalize it.) One of the most-searched for beauty gifts of the season, revealed (this one might surprise you!) Get social with us and let us know what you think of the episode! Find us on Instagram, Tiktok,X, Threads. Join our private Facebook group. Or give us a call and leave us a voicemail at 1-844-227-0302. Sign up for our Substack here For any products or links mentioned in this episode, check out our website: https://breakingbeautypodcast.com/episode-recaps/ Related episodes like this: Shop Smarter, Not Harder – How-to Get Real Value from Your Beauty Buys

This month, the gals bless us with their long-time bestie, the famous Blortney! Topics include guinea pig parties, overturned monkeys, a poopy pants puzzle, and eyebrow innovation. Don't be a stinker and a meanie, tune in for November's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.

CAR T therapy has delivered remarkable results for people with certain blood cancers—sometimes sending aggressive disease into deep remission after a single infusion. But today, only about 20% of eligible patients can actually get it. In this episode, sponsored by our partners at Allogene Therapeutics, Katie sits down with Dr. Zachary Roberts to unpack why access remains so limited and how new allogeneic (or “off-the-shelf”) CAR T therapies could be a turning point. They discuss how using healthy donor T-cells, rather than a patient’s own, may help bypass manufacturing hurdles and bring advanced treatment to more oncologists, more hospitals, and more communities. To learn more, visit Alpha3trial.com. #AllogenePartnerSee omnystudio.com/listener for privacy information.